

1 **Title**

2 **Multiomic Body Mass Index signatures in blood reveal clinically relevant population**
3 **heterogeneity and variable responses to a healthy lifestyle intervention**
4

5 **Authors**

6 Kengo Watanabe¹, Tomasz Wilmanski¹, Christian Diener¹, John C. Earls^{1,2}, Anat Zimmer^{1,†}, Briana
7 Lincoln¹, Jennifer J. Hadlock¹, Jennifer C. Lovejoy¹, Sean M. Gibbons^{1,3,4}, Andrew T. Magis¹, Leroy
8 Hood^{1,5}, Nathan D. Price^{1,2}, and Noa Rappaport^{1,*}
9

10 **Affiliations**

11 ¹Institute for Systems Biology, Seattle, WA 98109, USA.

12 ²Thorne HealthTech, New York, NY 10019, USA.

13 ³Department of Bioengineering, University of Washington, Seattle, WA 98195, USA.

14 ⁴eScience Institute, University of Washington, Seattle, WA 98195, USA.

15 ⁵Phenome Health, Seattle, WA 98109, USA.

16 [†]Present address: Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
17 Seattle, WA 98109, USA.

18 ^{*}Correspondence to Noa Rappaport (noa.rappaport@isbscience.org)
19

20 **Abstract**

21 Multiomic profiling can reveal population heterogeneity for both health and disease states. Obesity
22 drives a myriad of metabolic perturbations in individuals and is a risk factor for multiple chronic
23 diseases. Here, we report a global atlas of cross-sectional and longitudinal changes in 1,111 blood
24 analytes associated with variation in Body Mass Index (BMI), as well as the multiomic associations
25 with host polygenic risk scores and gut microbiome composition, from a cohort of 1,277 individuals
26 enrolled in a wellness program. Machine learning model predictions of BMI from blood multiomics
27 captured heterogeneous phenotypic states of host metabolism and gut microbiome composition, better
28 than classically-measured BMI. Moreover, longitudinal analyses identified variable BMI trajectories
29 for different omics measures in response to a healthy lifestyle intervention; metabolomics-inferred
30 BMI decreased to a greater extent than actual BMI, while proteomics-inferred BMI exhibited greater
31 resistance to change. Our analyses further revealed blood analyte–analyte associations that were
32 significantly modified by metabolomics-inferred BMI and partially reversed in the metabolically
33 obese population during the intervention. Taken together, our findings provide a blood atlas of the
34 molecular perturbations associated with changes in obesity status, serving as a valuable resource to
35 robustly quantify metabolic health for predictive and preventive medicine.
36

37 Introduction

38 Obesity has been increasing in prevalence over the past four decades in adults, adolescents, and
39 children around most of the world^{1,2}. Many studies have demonstrated that obesity is a major risk
40 factor for multiple chronic diseases such as type 2 diabetes mellitus (T2DM), metabolic syndrome
41 (MetS), cardiovascular disease (CVD), and certain types of cancer^{3–6}. In individuals with obesity, even
42 a 5% loss in body weight can improve metabolic and cardiovascular health⁷, and weight loss through
43 lifestyle interventions can reduce the risk for obesity-related chronic diseases⁸. Nevertheless, obesity
44 and its physiological manifestations can vary widely across individuals, necessitating additional
45 research to better understand this prevalent health condition.

46 Most commonly, obesity is quantified using the anthropometric Body Mass Index (BMI),
47 defined as the body weight divided by body height squared [kg m^{-2}]. While BMI does not directly
48 measure body composition, BMI correlates well at the population level with direct measurements of
49 body fat percentage using computed tomography (CT), magnetic resonance imaging (MRI), or dual-
50 energy X-ray absorptiometry (DXA) (partial Pearson's $r = 0.74–0.84$)⁹. As an easily calculated and
51 commonly understood measure among researchers, clinicians, and the general public, BMI is widely
52 used for the primary diagnosis of obesity, and changes in BMI are often used to assess the efficacy of
53 lifestyle interventions.

54 At the same time, there are considerable limitations to BMI as a surrogate measure of health
55 state; e.g., differences in body composition can lead to misclassification of people with a high muscle-
56 to-fat ratio (e.g., athletes) as the individual with obesity, and can undervalue metabolic improvements
57 in health following exercise¹⁰. A meta-analysis showed that the common obesity diagnoses based on
58 BMI cutoffs had high specificity but low sensitivity in identifying individuals with excess body fat¹¹.
59 The misclassification is likely due, in part, to the differences in BMI thresholds for obesity across
60 different ethnic populations¹², as well as the existence of a metabolically unhealthy, normal-weight
61 (MUNW) group within the normal BMI class^{13,14}. Likewise, there are health-heterogeneous groups
62 among the individuals with obesity: metabolically healthy obese (MHO) and metabolically unhealthy
63 obese (MUO). While most individuals in the MHO group are not necessarily healthy but simply
64 healthier than individuals in the MUO group¹⁵, the transition from MHO to MUO phenotype may be a
65 preceding step to the development of obesity-related chronic diseases¹⁶. Moreover, this transition is
66 potentially preventable through lifestyle interventions¹⁷. Altogether, BMI is unequivocally useful at
67 the population level, but too crude to capture a variety of heterogeneous metabolic health states.

68 Recent omics studies have demonstrated how blood omic profiles contain information
69 relevant to a wide range of human health conditions; e.g., blood proteomics captured 11 health
70 indicators such as the liver fat measured by ultrasound and the body composition measured by DXA¹⁸,
71 while blood metabolomics tended to reflect dietary intake, lifestyle patterns, and gut microbiome
72 profiles^{19,20}. Intriguingly, a machine learning model that was trained to predict BMI using 49 BMI-
73 associated blood metabolites captured obesity-related clinical measurements (e.g., insulin resistance,
74 visceral fat percentage) better than observed BMI or genetic predisposition for high BMI²¹. Moreover,
75 in a recent study on coronary artery disease, another blood metabolomics-based model of BMI
76 efficiently reflected differences between individuals with or without acute coronary syndrome
77 (ACS)²². Thus, while a single targeted metric (e.g., body composition) or a specific biomarker (e.g.,
78 leptin, adiponectin²³) provides useful information, multiomic blood profiling has the potential to
79 comprehensively bridge the multifaceted gaps between BMI and heterogeneous physiological states.

80 In this study, we report heterogeneous molecular signatures of obesity by leveraging a cohort
81 of 1,277 individuals with a wealth of phenotypic data, including human genomes and longitudinal
82 measurements of metabolomics, proteomics, clinical laboratory tests, gut microbiomes, physical
83 activity (i.e., wearables), and health/lifestyle questionnaires, and by employing machine learning to
84 predict BMI. Blood-based analytes across all studied omics platforms exhibit strong performance in
85 predicting measured BMI, explaining 48–78% of the variance in our main study cohort. We further
86 show that multiomic phenotyping captures more refined levels of heterogeneity in metabolic states
87 accompanying obesity, which is not apparent when using measured BMI. Moreover, longitudinal

88 analyses demonstrate variable changes in blood analytes across the studied omics platforms during a
89 healthy lifestyle intervention; i.e., plasma metabolomics exhibited a stronger response to the
90 intervention than measured BMI, while plasma proteomics exhibited a weaker response within a one-
91 year span. Our findings highlight the utility and translational potential of blood multiomic profiling for
92 investigating the complex molecular phenotypes underlying obesity and weight loss.
93

94 Results

95 Plasma multiomics captured 48–78% of the variance in BMI

96 To investigate the molecular phenotypic perturbations associated with obesity, we selected a study
97 cohort of 1,277 adults who participated in a scientific wellness program (Arivale)^{20,24–29} and whose
98 datasets included coupled measurements of plasma metabolomics, proteomics, and clinical laboratory
99 tests from the same blood draw (Fig. 1a; see Methods). This study design allowed us to directly
100 investigate the similarities and differences between omics platforms with regards to how they reflected
101 the physiological health state of each individual across the BMI spectrum. This cohort was
102 characteristically female (64.3%), middle-aged (mean \pm s.d.: 46.6 ± 10.8 years), and white (69.7%)
103 (Supplementary Fig. 1a–c, Supplementary Data 1). Based on the World Health Organization (WHO)
104 international standards for BMI cutoffs (underweight: $<18.5 \text{ kg m}^{-2}$, normal: $18.5\text{--}25 \text{ kg m}^{-2}$,
105 overweight: $25\text{--}30 \text{ kg m}^{-2}$, obese: $\geq 30 \text{ kg m}^{-2}$)¹², the baseline BMI prevalence was similar among
106 normal, overweight, and obese classes, while only 0.8% of participants were in the underweight class
107 (underweight: 10 participants (0.8%), normal: 426 participants (33.4%), overweight: 391 participants
108 (30.6%), obese: 450 participants (35.2%)).

109 Leveraging the baseline measurements of plasma molecular analytes (766 metabolites, 274
110 proteins, and 71 clinical laboratory tests; Supplementary Data 2), we trained machine learning models
111 to predict baseline BMI (i.e., not forecast a future outcome but calculate an out-of-sample outcome)
112 for each of the omics platforms (metabolomics, proteomics, and clinical labs) or in combination
113 (combined omics of all metabolomics, proteomics, and clinical labs): metabolomics-based,
114 proteomics-based, clinical labs (chemistries)-based, and combined omics-based BMI (MetBMI,
115 ProtBMI, ChemBMI, and CombiBMI, respectively) models. To address multicollinearity among the
116 analytes (Supplementary Fig. 2a) and to obtain predictions for all participants, we applied a tenfold
117 iteration scheme of the least absolute shrinkage and selection operator (LASSO) algorithm with
118 tenfold cross-validation (CV) (Fig. 1a; see Methods). This approach generated ten fitted sparse models
119 for each omics category (Supplementary Data 3) and one single testing (hold-out) set-derived
120 prediction from each omics category for each participant. The resulting models retained (i.e., assigned
121 non-zero β -coefficient to) 62 metabolites, 30 proteins, 20 clinical laboratory tests, and 132 analytes
122 across all ten MetBMI, ProtBMI, ChemBMI, and CombiBMI models, respectively, which exhibited
123 low collinearity (Supplementary Fig. 2b, c) as expected from the LASSO algorithm³⁰. In contrast to a
124 model including obesity-related standard clinical measures (i.e., ordinary least squares (OLS) linear
125 regression model with sex, age, triglycerides, high-density lipoprotein (HDL)-cholesterol, low-density
126 lipoprotein (LDL)-cholesterol, glucose, insulin, and homeostatic model assessment for insulin
127 resistance (HOMA-IR) as regressors; StandBMI model), each omics-based model demonstrated
128 significantly higher performance in BMI prediction, ranging from out-of-sample $R^2 = 0.48$
129 (ChemBMI) to 0.70 (ProtBMI) compared to 0.37 (StandBMI) (Fig. 1b, c). The CombiBMI model
130 exhibited the best performance in BMI prediction (out-of-sample $R^2 = 0.78$; Fig. 1c), but the variances
131 explained were not completely additive, suggesting that, although there is a considerable overlap in
132 the signal detected by each omics platform, different omic measurements still contain non-redundant
133 information regarding BMI. Additionally, these results were consistent in sex-stratified models, with
134 the exception of male ChemBMI model that tended to exhibit higher performance than StandBMI
135 model without statistical significance (Supplementary Fig. 2d).

136 To confirm the generalizability of our results, we investigated an external cohort of 1,834
137 adults from the TwinsUK registry³¹, whose datasets included serum metabolomics³² and the
138 aforementioned standard clinical measures (Fig. 1a; see Methods). This external cohort was

139 demographically distinct from the Arivale cohort (Supplementary Fig. 1d–f, Supplementary Data 1);
140 the TwinsUK cohort was overwhelmingly female (96.7%), senior (mean \pm s.d.: 61.4 \pm 9.0 years), and
141 white (99.2%), and consisted of 15 (0.8%), 779 (42.5%), 706 (38.5%), and 334 (18.2%) participants in
142 the underweight, normal, overweight, and obese BMI classes, respectively. To manage the differences
143 in the metabolomics panels, we regenerated MetBMI models in the Arivale cohort, while restricting
144 the metabolomic features to an overlapping set of 489 metabolites between the Arivale and TwinsUK
145 panels (called restricted model). Although 25 of the retained metabolites in the original MetBMI
146 models were replaced with other metabolites due to their absences in the restricted panel, 35 of the
147 remaining 37 metabolites were consistently retained across the restricted MetBMI models
148 (Supplementary Fig. 3a). Moreover, β -coefficients for the retained metabolites and MetBMI
149 predictions for the Arivale cohort were consistent between the original and restricted models
150 (Supplementary Fig. 3b, c). We then calculated BMI predictions for the TwinsUK cohort using the
151 StandBMI and restricted MetBMI models that were fitted to the Arivale datasets. The restricted
152 MetBMI model exhibited a lower absolute performance on the TwinsUK cohort compared to the
153 Arivale cohort, but a significantly higher performance than StandBMI model (out-of-sample $R^2 = 0.30$
154 (MetBMI), -0.13 (StandBMI); Fig. 1d, Supplementary Fig. 3d), confirming that blood metabolomics
155 generally captures BMI better than the standard clinical measures.

156 BMI has been reported to be associated with multiple anthropometric and clinical measures,
157 such as waist circumference (WC), blood pressure, sleep quality, and several polygenic risk scores
158 (PRSs)^{3,4,15,27,33}. Thus, we examined the association between the omics-inferred BMI and each of the
159 available numeric physiological measures (see Methods; Supplementary Data 4). Among the 51
160 assessed features, measured BMI was significantly associated with 27 features (false discovery rate
161 (FDR) < 0.05) including daily physical activity measures from wearable devices, waist-to-height ratio
162 (WHtR), blood pressure, and BMI PRS (Fig. 1e). With minor differences in effect sizes, these BMI-
163 associated features were concordantly associated with each omics-inferred BMI (Fig. 1e), indicating
164 that the omics-inferred BMIs primarily maintain the characteristics of classical BMI in terms of
165 anthropometric, genetic, lifestyle, and physiological associations.
166

167 **Omics-based BMI estimates captured the variation in BMI better than any single analyte**

168 Because our LASSO linear regression model showed comparable performance to elastic net (EN) and
169 ridge linear regression models and a non-linear random forest (RF) regression model (Supplementary
170 Fig. 4a, b) and because LASSO model β -coefficients are generally easier to be interpreted, we chose
171 to focus on the LASSO models. However, the LASSO algorithm randomly retains variables from
172 highly collinear groups, and sets β -coefficients of the other variables to zero. To confirm the
173 robustness of the variable selection process, we iterated the LASSO modeling while removing the
174 strongest analyte (i.e., the analyte that had the highest absolute value for the mean of the ten β -
175 coefficients) from the input omic dataset at the end of each iteration. If a variable is indispensable for
176 a model, the performance should largely decrease after removing it. In all omics categories, a steep
177 decay in the out-of-sample R^2 was observed in the first 5–9 iterations (Supplementary Fig. 2e–h),
178 suggesting that, at least, the top 5–9 variables that had the highest absolute β -coefficient values in the
179 original LASSO models were indispensable for predicting BMI. Interestingly, the overall slope of R^2
180 in MetBMI model decayed more gradually compared to ProtBMI and ChemBMI models
181 (Supplementary Fig. 2e–g), implying that metabolomics data contain more redundant information
182 about BMI than the other omics data. Although larger number of metabolites in the input dataset
183 might be a plausible explanation, the proportion of the variables that were robustly retained across all
184 ten LASSO models (Supplementary Fig. 5) to the variables that were retained in at least one of the ten
185 LASSO models was lower in MetBMI model compared to ProtBMI and ChemBMI models (MetBMI:
186 62/209 metabolites $\approx 30\%$, ProtBMI: 30/74 proteins $\approx 41\%$, ChemBMI: 20/41 clinical laboratory tests
187 $\approx 49\%$), confirming the higher level of redundancy within metabolomics data. Nevertheless,
188 metabolites still constituted 58% of the 132 analytes that were retained across all ten CombiBMI
189 models (77 metabolites, 51 proteins, 4 clinical laboratory tests; Fig. 2a), suggesting that each of the
190 omics categories possesses unique information about BMI. The strongest predictors in CombiBMI

191 model were primarily proteins; e.g., analytes having the mean absolute β -coefficient > 0.02 (i.e.,
192 affecting more than $\sim 2\%$ BMI in prediction per 1 s.d. of its change, according to the Taylor/Maclaurin
193 series: $e^\beta \approx 1 + \beta$ when $\beta \ll 1$) were leptin (LEP), adrenomedullin (ADM), and fatty acid-binding
194 protein 4 (FABP4) as the positive predictors and insulin-like growth factor-binding protein 1
195 (IGFBP1) and advanced glycosylation end-product specific receptor (AGER; also described as
196 receptor of AGE, RAGE) as the negative predictors. Note that these strongest proteins were consistent
197 in the EN models (Supplementary Fig. 4c–f) and had high importance in the ridge and RF models
198 (Supplementary Fig. 4g, h).

199 At the same time, the existence of these strong and consistently-retained predictors in the
200 omics-based BMI models implied that a single analyte might be a suitable biomarker to predict BMI.
201 To address this possibility, we regressed BMI independently on each of the analytes that were retained
202 in at least one of the ten LASSO models (MetBMI: 209 metabolites, ProtBMI: 74 proteins,
203 ChemBMI: 41 clinical laboratory tests; Supplementary Data 5). Among the analytes that were
204 significantly associated with BMI (180 metabolites, 63 proteins, 30 clinical laboratory tests), only
205 LEP, FABP4, and interleukin 1 receptor antagonist (IL1RN) exhibited over 30% of the explained
206 variance in BMI by themselves (Fig. 2b–d), with a maximum of 37.9% variance explained (LEP). In
207 contrast, MetBMI, ProtBMI, and ChemBMI models explained 68.9%, 70.6%, and 48.8% of the
208 variance in BMI, respectively. Moreover, even upon eliminating several strong predictor analytes such
209 as LEP and FABP4 from the omic datasets, the models still explained more variance in BMI than any
210 single analyte (Supplementary Fig. 2e–h). These results indicate that the multiomic BMI prediction
211 models explain a larger portion of the variation in BMI than any single analyte, and highlight the
212 multivariate perturbation of blood analytes across all platforms with increasing BMI.
213

214 **Metabolic heterogeneity was responsible for the high rate of misclassification within the** 215 **standard BMI classes**

216 While the omics-inferred BMIs showed the similar phenotypic associations as the measured BMI (Fig.
217 1e), we observed that the difference of the predicted BMI from the measured BMI (Δ BMI) was highly
218 correlated among the omics-based BMI models, ranging from Pearson's $r = 0.64$ (ChemBMI vs.
219 CombiBMI) to 0.83 (ProtBMI vs. CombiBMI) (Fig. 3a). In other words, the different omics
220 consistently detected deviation of the omics-inferred BMI from the measured BMI per individual,
221 implying that this deviation stemmed from a true biological signal of a perturbed physiological state
222 rather than from noise or modeling artifacts. Actually, when individuals in the normal and obese BMI
223 classes (defined by the WHO international standards) were subdivided by a clinical definition of
224 metabolic health (i.e., defining metabolically unhealthy if having two or more MetS risks of the
225 National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines; see
226 Methods)^{34,35}, Δ BMI was significantly higher in MUNW and MUO groups compared to metabolically
227 healthy, normal-weight (MHNW) and MHO groups, respectively, for all omics categories (Fig. 3b),
228 suggesting that the deviations of model predictions are related to metabolic health.

229 Nevertheless, there has been no universally accepted definition of metabolic health^{14,15,34,35}.
230 Thus, given the high interpretability and intuitiveness of the omics-inferred BMI, we further explored
231 a potential application: using the omics-inferred BMI (instead of the measured BMI) for improved
232 classification of both obesity and metabolic health with the WHO international standards. Each
233 participant was classified using each of the measured and omics-inferred BMIs based on the standard
234 BMI cutoffs, and categorized into either Matched or Mismatched group when the measured BMI class
235 was matched or mismatched to each omics-inferred BMI class, respectively. The misclassification rate
236 against the omics-inferred BMI class was $\sim 30\%$ across all omics categories and BMI classes (Fig. 3c),
237 consistent with the previously reported misclassification rates about the cardiometabolic health
238 classification^{36,37}. We then examined relationships between this omics-based misclassification within
239 normal or obese BMI class and the obesity-related clinical blood markers (Supplementary Data 6),
240 including triglycerides, HDL-cholesterol, LDL-cholesterol, high-sensitivity C-reactive protein (hs-
241 CRP), glucose, insulin, HOMA-IR, glycated hemoglobin A1c (HbA1c), adiponectin, and vitamin

242 D^{3,15,23,38,39}. Because ChemBMI and CombiBMI models were not independent of these markers, only
243 the misclassification against MetBMI or ProtBMI class was examined in this analysis. The
244 Mismatched group of normal BMI class exhibited significantly higher values of the markers that are
245 positively associated with BMI (+BMI), such as triglycerides, hs-CRP, glucose, and HOMA-IR, and
246 significantly lower values of the markers that are negatively associated with BMI (-BMI), such as
247 HDL-cholesterol and adiponectin, compared to the Matched group of normal BMI class (FDR < 0.05;
248 Fig. 3d). These patterns suggest that the participant misclassified into the normal BMI class possesses
249 less healthy molecular profiles as similarly as the individual with overweight or obesity,
250 corresponding to the individual with MUNW phenotype. Conversely, the Mismatched group of obese
251 BMI class exhibited significantly lower and higher values of the positively and negatively BMI-
252 associated markers, respectively, compared to the Matched group of obese BMI class (FDR < 0.05;
253 Fig. 3d), suggesting that the participant misclassified as obese BMI class has healthier blood
254 signatures, more similarly to the individual with overweight or normal-weight, corresponding to the
255 individual with MHO phenotype. Likewise, we re-examined the 27 BMI-associated numeric
256 physiological features (Fig. 1e, Supplementary Data 6), and found the concordant pattern of
257 significant phenotypic differences between Matched and Mismatched groups in WHtR (+BMI), heart
258 rate (+BMI), blood pressure (+BMI), and daily physical activity measures (-BMI) (FDR < 0.05; Fig. 3e).
259 Importantly, there was no difference in BMI PRS (+BMI) between Matched and Mismatched groups
260 (Fig. 3e), implying that lifestyle or environmental factors, rather than genetic risk, is likely involved in
261 the discordance between the measured and omics-inferred BMIs. Furthermore, we validated and
262 expanded these findings in the TwinsUK cohort: Δ MetBMI was significantly higher in the
263 metabolically unhealthy group compared to the metabolically healthy group within the normal BMI
264 class (Supplementary Fig. 6a); the misclassification rate against MetBMI class was much higher
265 (>60%) in the normal BMI class but ~30% in the others (Supplementary Fig. 6b); the concordant
266 phenotypic differences between Matched and Mismatched groups were significantly observed in
267 triglycerides (+BMI), HDL-cholesterol (-BMI), LDL-cholesterol (+BMI), hs-CRP (+BMI), and HOMA-IR
268 (+BMI) (FDR < 0.05; Supplementary Fig. 6c). Remarkably, while DXA measurements were not
269 performed in the Arivale cohort, the percentage of total fat in whole body (+BMI) and the ratio of fat in
270 android region to fat in gynoid region (+BMI) were significantly higher in Mismatched group compared
271 to Matched group within the normal BMI class of the TwinsUK cohort (FDR < 0.05; Supplementary
272 Fig. 6c). Taken together, these results suggest that the omics-based BMI models can identify
273 heterogeneous metabolic health states which are not captured by the measured BMI with the standard
274 BMI cutoffs.
275

276 **Metabolomics-inferred BMI reflected gut microbiome profiles better than BMI**

277 The gut microbiome has been shown to causally affect host obesity phenotypes in a mouse model⁴⁰,
278 and humans with obesity generally exhibit lower bacterial α -diversity (i.e., the species richness and/or
279 evenness of an ecological community)^{41,42}. However, certain meta-analyses of human case-control
280 studies suggest an inconsistent relationship between the gut microbiome and obesity^{43,44}. Given our
281 previous finding that the association between blood metabolites and bacterial diversity is dependent on
282 BMI²⁰ and the current finding that the omics-based BMI models capture heterogeneous metabolic
283 health states (Fig. 3), we hypothesized that MetBMI represents gut microbiome α -diversity better than
284 the measured BMI. For the 702 Arivale participants who had both stool-derived gut microbiome and
285 blood omic datasets (Fig. 4a; see Methods), we examined relationships between gut microbiome α -
286 diversity (the number of observed species, Shannon's index, and Chao1 index) and the omics-based
287 BMI misclassification. Matched and Mismatched groups against MetBMI class showed significant
288 differences in all α -diversity metrics within both normal and obese BMI classes (Fig. 4b), with the
289 concordant pattern to the clinical markers and BMI-associated features (-BMI; e.g., HDL-cholesterol;
290 Fig. 3d, e), implying that the MetBMI class reflects bacterial diversity better than BMI class.
291 Interestingly, the misclassification against the other omics categories did not show these significant
292 differences for all α -diversity metrics and both BMI classes (Fig. 4b), consistent with our previous

293 observation that plasma metabolomics showed a much stronger correspondence to gut microbiome
294 structure than either proteomics or clinical labs²⁰.

295 We further examined the predictive power of gut microbiome profiles for MetBMI. For each
296 of the measured BMI and MetBMI classes, we generated models classifying individuals into normal
297 class versus obese class based on gut microbiome 16S rRNA gene amplicon sequencing data, using a
298 fivefold iteration scheme of the RF algorithm with fivefold CV (Fig. 4a; see Methods). Compared to
299 the classifier for the measured BMI class, the classifier for MetBMI class showed significantly larger
300 area under curve (AUC) in the receiver operator characteristic (ROC) curve in the Arivale cohort
301 (AUC = 0.66 (BMI), 0.75 (MetBMI); Fig. 4c), with significantly higher sensitivity and precision (Fig.
302 4d). Moreover, by applying the same scheme to the stool-derived whole metagenomic shotgun
303 sequencing (WMGS) data of the 329 TwinsUK participants⁴⁵ (Fig. 4a; see Methods), we validated that
304 the gut microbiome-based obesity classifier for MetBMI class significantly outperformed the classifier
305 for the measured BMI class in the TwinsUK cohort (AUC = 0.57 (BMI), 0.75 (MetBMI); Fig. 4e, f).
306 Note that these classifiers were regenerated for the TwinsUK cohort (instead of using the classifiers
307 that were fitted to the Arivale dataset; Fig. 4a) due to the difference in sequencing methods (amplicon
308 sequencing vs. WMGS), while considering that the TwinsUK participants' MetBMIs were predicted
309 from the Arivale-fitted MetBMI models (Fig. 1a). Altogether, these findings suggest that, although
310 other factors (e.g., dietary intake¹⁹) may be involved, MetBMI has a stronger correspondence to gut
311 microbiome features than the standard BMI.
312

313 **Metabolic health of the metabolically obese group was substantially improved following a** 314 **healthy lifestyle intervention**

315 In the Arivale program, healthy lifestyle coaching was provided to all participants, resulting in clinical
316 improvement across multiple measures of health²⁵. This coaching intervention was personalized for
317 each participant to improve the participant's health based on the combination of clinical laboratory
318 tests, genetic predispositions, and published scientific evidence, and administered via telephone by
319 registered dietitians, certified nutritionists, or registered nurses (see Methods and a previous report²⁵).
320 To investigate the longitudinal changes in omic profiles during the program, we defined a sub-cohort
321 of 608 participants based on the available longitudinal measurements (Fig. 5a; see Methods). Given
322 the participant-dependent variability in both count and time point of data collections, we estimated the
323 average trajectory of each measured or omics-inferred BMI in the Arivale sub-cohort using a linear
324 mixed model (LMM) with random effects for each participant (see Methods). Consistent with the
325 previous analysis^{25,46}, the mean BMI estimate for the overall cohort decreased during the program
326 (Fig. 5b). The decrease of MetBMI was larger than that of measured BMI, while the decrease of
327 ProtBMI was minimal and even smaller than that of measured BMI (Fig. 5b), suggesting that plasma
328 metabolomics is highly responsive to the lifestyle intervention in the short term, while proteomics
329 (measured from the same blood draw) is more resistant to change during the same intervention period.
330 Subsequently, we generated LMMs with the baseline BMI class stratification, and confirmed that a
331 significant decrease in the mean BMI estimate was observed in the overweight and obese BMI classes,
332 but not in the normal BMI class (Fig. 5c). Concordantly, the mean estimates of ProtBMI and
333 ChemBMI exhibited negative changes over time in the overweight and obese BMI classes, but not in
334 the normal BMI class (Fig. 5c). In contrast, the mean estimate of MetBMI exhibited a significant
335 decrease across all BMI classes (Fig. 5c), suggesting that metabolomics data captures information
336 about the metabolic health response to the lifestyle intervention, beyond the baseline BMI class and
337 the changes in BMI and other omic profiles.

338 Given the existence of multiple metabolic health sub-states within the standard BMI classes
339 (Fig. 3), we further investigated the difference between misclassification strata against the baseline
340 MetBMI class. In the (baseline) normal BMI class, while the mean estimate of the measured BMI
341 remained constant in both Matched and Mismatched groups, the mean MetBMI estimate exhibited
342 larger reduction in Mismatched group than Matched group (Fig. 5d), suggesting that the participants
343 with MUNW phenotype improved their metabolic health to a greater extent than the participants with

344 MHNW phenotype. Likewise, in the (baseline) obese BMI class, while the decrease in the mean
345 estimate of the measured BMI was not significantly different between Matched and Mismatched
346 groups at one year after the enrollment, the decrease in the mean MetBMI estimate was larger in
347 Matched group than in Mismatched group (Fig. 5e), suggesting that the participants with MUO
348 phenotype improved their metabolic health to a greater extent than the participants with MHO
349 phenotype. Altogether, these results suggest that metabolic health was substantially improved during
350 the program, in accordance with an individual's baseline metabolomic state, rather than with the
351 individual's baseline BMI class.
352

353 **Plasma analyte correlation network in the metabolically obese group shifted toward a structure** 354 **observed in metabolically healthier state following a healthy lifestyle intervention**

355 We explored longitudinal changes in plasma analyte correlation networks, focusing on the
356 metabolically obese group. Based on the importance of the baseline metabolomic state (Fig. 5d, e), we
357 first assessed relationships between each plasma analyte–analyte correlation and the baseline MetBMI
358 within the Arivale sub-cohort (Fig. 5a; 608 participants), using their interaction term in a generalized
359 linear model (GLM; see Methods) of each analyte–analyte pair. In this type of model, the statistical
360 test assesses whether the relationship between any two analytes is dependent on a third variable (in
361 this case, the baseline MetBMI). Among 608,856 pairwise relationships of plasma analytes, 100
362 analyte–analyte correlation pairs, comprising 82 metabolites, 33 proteins, and 16 clinical laboratory
363 tests, were significantly modified by the baseline MetBMI (FDR < 0.05; Supplementary Data 7).
364 Subsequently, we assessed longitudinal changes of these 100 pairs within the metabolically obese
365 group (i.e., the baseline obese MetBMI class; 182 participants), using the interaction term (i.e.,
366 interaction with days in the program) in a generalized estimating equation (GEE; see Methods) of each
367 analyte–analyte pair. Among the 100 pairs, 27 analyte–analyte correlation pairs were significantly
368 modified by days in the program (FDR < 0.05; Fig. 6a, Supplementary Data 7). These 27 pairs were
369 mainly derived from metabolites (21 metabolites, 3 proteins, 3 clinical laboratory tests). One of these
370 time-varying pairs was homoarginine and phenyllactate (PLA). Homoarginine was recently found to
371 be a biomarker for CVD⁴⁷ and was a robustly retained positive predictor in MetBMI and CombiBMI
372 models (Fig. 2a, Supplementary Fig. 5a). PLA is a gut microbiome-derived phenylalanine derivative
373 known to have antimicrobial activity and antioxidant activity^{48,49}. The positive correlation between
374 homoarginine and PLA was observed in the metabolically obese group at baseline (Fig. 6b) and
375 became weaker in this group during the course of the intervention (Fig. 6c), implying that metabolic
376 dysregulation specific to the metabolically obese group was somewhat improved during the program.
377 Collectively, these findings indicate that metabolic improvement was not limited to changes in
378 specific blood analyte concentrations but also changes in the association structure among analytes.
379

380 **Discussion**

381 Obesity is a significant risk factor for many chronic diseases^{3–6}. The heterogeneous nature of human
382 health conditions, with variable manifestation ranging from metabolic abnormalities to cardiovascular
383 symptoms, calls for deeper molecular characterizations in order to optimize wellness and reduce the
384 current global epidemic of chronic diseases. In this study, we have demonstrated that obesity
385 profoundly perturbs human physiology, as reflected across all the studied omics modalities. The key
386 findings of this study are: (1) machine learning-based multiomic BMI estimates were better suited to
387 identifying heterogeneous metabolic health than the classically-measured BMI, while maintaining a
388 high level of interpretability and intuitiveness attributed to the original metric (Fig. 1–3); (2) among
389 all omics studied, metabolomic reflection of obesity exhibited the strongest correspondence to gut
390 microbiome community structure (Fig. 4); (3) plasma metabolomics exhibited the strongest (and/or
391 earliest) response to lifestyle coaching, while plasma proteomics exhibited a weaker (and/or more
392 delayed) response than the measured BMI (Fig. 5b, c); (4) compared to the participants with
393 metabolically healthy phenotype (i.e., BMI class = MetBMI class), the participants with metabolically
394 unhealthy phenotype (i.e., BMI class < MetBMI class) exhibited a greater improvement in their

395 metabolic health (but not in weight loss per se) in response to the healthy lifestyle coaching (Fig. 5d,
396 e); (5) dozens of analyte–analyte associations were modified in the participants of the metabolically
397 obese group (i.e., obese MetBMI class), following the healthy lifestyle intervention (Fig. 6).

398 Although BMI is used as a measure of obesity, fat distribution in the body is an important
399 factor for understanding the heterogeneous nature of obesity. In particular, abdominal obesity, which
400 is characterized by excessive visceral fat (rather than subcutaneous fat) around the abdominal region,
401 is known to be associated with chronic diseases such as MetS⁵⁰. Thus, we addressed abdominal
402 obesity by analyzing the anthropometric WHtR^{51,52}, which was highly correlated with BMI in the
403 Arivale sub-cohort (Pearson's $r = 0.86$; Supplementary Fig. 7a–c). We generated omics-based WHtR
404 models (Supplementary Fig. 7a, Supplementary Data 8), and obtained consistent findings to the
405 omics-based BMI models (Supplementary Fig. 7d–m). Interestingly, the majority of the retained
406 analytes in each omics-based WHtR model was also retained in its corresponding omics-based BMI
407 model with the similar feature importance (Supplementary Fig. 8a–d). In addition, Δ WHtR was highly
408 correlated with Δ BMI across all omics categories (Supplementary Fig. 8e). Moreover, although the
409 WC measurements were not available for the defined TwinsUK cohort, direct fat measurements of the
410 android region by DXA were associated with MetBMI class in the TwinsUK cohort (Supplementary
411 Fig. 6c). Therefore, although BMI requires complementary information of the WC-related
412 measurements for the diagnosis of abdominal obesity, the omics-based BMI model likely captures the
413 obesity characteristics including abdominal obesity.

414 Multiple observational studies have explored obesity biomarkers. The involvements of
415 insulin/insulin-like growth factor (IGF) axis and chronic low-grade inflammation have been discussed
416 in the context of obesity-related disease risks^{5,6}, backed up by robust associations of obesity with
417 IGFBP1/2 ($-_{\text{BMI}}$), adipokines such as LEP ($+_{\text{BMI}}$), adiponectin ($-_{\text{BMI}}$), FABP4 ($+_{\text{BMI}}$), and ADM
418 ($+_{\text{BMI}}$), and proinflammatory cytokines such as interleukin 6 (IL6; $+_{\text{BMI}}$)^{23,53}. Consistent with these
419 well-known associations, we observed positive BMI associations with LEP, FABP4, IL1RN, IL6,
420 ADM, and insulin and negative BMI associations with IGFBP1/2 and adiponectin (Fig. 2c, d).
421 Importantly, all these known biomarkers were incorporated into our omics-based BMI models, and
422 most of them were consistently retained as important features of these models (Fig. 2a; Supplementary
423 Fig. 5b, c). At the same time, we observed that RAGE explained a relatively small proportion of the
424 variance in BMI (Fig. 2c), while being a strong negative predictive feature in all ten models of
425 ProtBMI and CombiBMI (Fig. 2a, Supplementary Fig. 5b). Soluble RAGE (sRAGE) has been
426 gradually highlighted in the contexts of T2DM and CVD⁵⁴, with several reports on the negative
427 association between sRAGE and BMI⁵⁵. Therefore, omics-inferred BMI may reflect not only obesity
428 status but also the early transition towards clinical manifestations of obesity-related chronic diseases.

429 Likewise, many epidemiological studies have revealed metabolomic biomarkers for
430 obesity^{56,57}. In line with these previous findings, we have confirmed positive BMI associations with
431 mannose, uric acid (urate), and glutamate and negative BMI associations with asparagine and glycine
432 (Fig. 2b). Furthermore, all of these metabolites were consistently incorporated into all ten models of
433 MetBMI and CombiBMI (Fig. 2a, Supplementary Fig. 5a). In addition, many lipids emerged as strong
434 predictors in MetBMI and CombiBMI models; in particular, glycerophosphocholines (GPCs) were
435 negative predictors in these models, while sphingomyelins (SMs) were positive predictors (Fig. 2a,
436 Supplementary Fig. 5a), even though both have a phosphocholine group in common. Although lipid
437 has traditionally been regarded as a factor that is positively associated with obesity, recent
438 metabolomics studies have revealed variable trends for different fatty acid species; e.g., plasma
439 lysophosphatidylcholines (LPCs) are decreased in mice with obesity (high-fat diet model)⁵⁸, which
440 corresponded well with our results (e.g., LPC(18:1), described as 1-oleoyl-GPC(18:1) in Fig. 2b and
441 Supplementary Fig. 5b). However, because there are many combinations of acyl residues in lipids and
442 many potential confounding factors with obesity, systematic understanding of the species-level lipid
443 biomarkers for obesity remains challenging^{56,57}. Our approach, applying machine learning to
444 metabolomics data, addresses this challenge by automatically and systematically providing a
445 molecular signature of obesity, reflecting the versatile and complex metabolite species. Altogether,

446 omics-based BMI models can be regarded as multidimensional profiles of obesity, possessing detailed
447 mechanistic information.

448 Recently, Cirulli and colleagues have reported a machine learning model for estimating BMI
449 from blood metabolomics, which captured obesity-related phenotypes²¹. Their main model explained
450 39.1% of the variance in BMI, while our MetBMI model explained 68.9% of the variance in BMI
451 (Fig. 2b). Other than the difference in cohorts, the performance gap is likely a result of differences in
452 modeling strategies. Cirulli and colleagues stringently selected 49 metabolites, out of their
453 metabolomics panel of 1,007 metabolites, based on a pre-screening for significant adjusted-
454 associations with BMI, and subsequently applied a tenfold CV implementation of ridge or LASSO
455 method. In contrast, we used LASSO method for feature selection, applying it to our full
456 metabolomics panel of 766 metabolites. In addition to the increased number of metabolites included in
457 the model fitting, our higher performance may stem from the presence of metabolites which were
458 critical for BMI prediction in a multivariate model, but not strongly associated with BMI on their own.
459 Actually, similarly to the above example of RAGE in ProtBMI model, our MetBMI model contained
460 multiple metabolites that were weakly associated with BMI but consistently retained across all ten
461 models (Fig. 2b, Supplementary Fig. 5a). At the same time, the majority of the 49 metabolites reported
462 by Cirulli and colleagues (14–20 metabolites among the 31–41 corresponding metabolites in our
463 metabolomics panel) were retained in at least one of the ten MetBMI models. Therefore, our strategy
464 of feature selection through machine learning, without a pre-filtering step, may be preferable for
465 predicting BMI from metabolomics.

466 A recent study investigating multiomic changes in response to weight perturbations
467 demonstrated that some weight gain-associated blood signatures were reversed during subsequent
468 weight loss, while others persisted⁵⁹. Interestingly, we found that MetBMI was more responsive to the
469 healthy lifestyle intervention than the measured BMI or ChemBMI, while ProtBMI was more resistant
470 to the same intervention (Fig. 5b, c). Our analyses of the predictors in the omics-based BMI models
471 (Fig. 2; Supplementary Fig. 2e–h, 5) suggested that the distribution of feature importance among
472 metabolites was considerably wider, while only a small subset of measured proteins (~5 proteins) was
473 predominantly reflective of obesity profiles. Therefore, the effect of lifestyle coaching may consist of
474 small additive contributions in blood metabolites in the short term. However, a longer longitudinal
475 analysis is needed to infer the physiological meaning of these omics-dependent dynamics. For
476 instance, it is possible that ProtBMI shows a delayed response to weight loss (over a span greater than
477 a year measured presently; Fig. 5b, c), indicating blood metabolites and proteins may be early and late
478 responders to a lifestyle intervention, respectively, such as in the case of the changes in blood glucose
479 compared to the changes in HbA1c when assessing glucose homeostasis⁶⁰. If the difference between
480 the measured and omics-inferred BMIs remains constant even after one year, we would conclude that
481 blood metabolites and proteins are more and less sensitive to weight loss than the measured BMI,
482 respectively. In either scenario, monitoring blood multiomics during weight loss programs could help
483 participants maintain their motivation to stay engaged with persistent lifestyle changes, because they
484 would receive rapid feedback on how lifestyle changes were impacting their health, even in the
485 absence of weight loss. In addition, long-term maintenance of the improvement is an important
486 challenge for lifestyle interventions; although there is variability between prior reports, one study
487 estimated that only ~20% of the individuals with overweight successfully maintain their weight loss in
488 post-intervention⁶¹. Despite this relatively low rate of long-term success, there is evidence that
489 lifestyle interventions had benefits in preventing diabetes incidence as far as 20 years post-
490 intervention, even if weight was regained^{62,63}. The observed larger improvement of MetBMI
491 compared to the measured BMI could potentially contribute to this protective long-term effect,
492 persisting even when weight is regained. Further investigation is required, especially with regard to
493 the long-term dynamics of MetBMI and ProtBMI responses, which may provide a foothold in
494 developing scientific strategies aimed at long-term maintenance of metabolic health.

495 Despite a number of highly promising findings, there were several limitations to our study.
496 For example, this study was not designed as a randomized control trial, and we cannot strictly evaluate
497 the effectiveness of the lifestyle intervention (e.g., bigger improvements in the obese group compared

498 to the normal-weight group may be due to the regression-toward-the-mean effect⁴⁶). In addition, we
499 used time as the variable in longitudinal analyses under an assumption that the program enrollment
500 itself affected participant's BMI and omic profiles. However, if we had more detailed data on the
501 intervention (e.g., magnitude, participants' compliance), we would be able to improve the assessment
502 of its effect. The generalizability of our findings may be limited, because this study was an
503 observational study of largely Caucasian cohorts from the Pacific West of the U.S. and from the U.K.
504 and because validation with an external cohort relied on the female-dominated cohort (96.7%) and its
505 metabolomics data. Our measurements did not cover all biomolecules in blood; in particular,
506 proteomics was based on three targeted Olink panels. Thus, our findings on metabolomic and
507 proteomic states are restricted to the analytes that we could measure. Nevertheless, this study will
508 serve as a valuable resource for robustly characterizing metabolic health from the blood and
509 identifying actionable targets for health management.
510

511 **Methods**

512 **Study cohort**

513 The main study cohort (Arivale cohort) was derived from 6,223 individuals who participated in a
514 wellness program offered by a currently closed commercial company (Arivale Inc., Washington,
515 USA) between 2015–2019. An individual was eligible for enrollment if the individual was over 18
516 years old, not pregnant, and a resident of any U.S. state except New York; participants were primarily
517 recruited from Washington, California, and Oregon. The participants were not screened for any
518 particular disease. During the Arivale program, each participant was provided personalized lifestyle
519 coaching via telephone by registered dietitians, certified nutritionists, or registered nurses. This
520 coaching was designed to improve the participant’s health based on the combination of clinical
521 laboratory tests, genetic predispositions, and published scientific evidence; e.g., reduction of sodium
522 intake might be recommended to any participants with high blood pressure, but if they also had risk
523 alleles indicating enhanced susceptibility to dietary sodium, this risk would be emphasized (see a
524 previous report²⁵ for more details). In the current study, to compare the associations between Body
525 Mass Index (BMI) and host phenotypes across different omics, we limited the original cohort to the
526 participants whose datasets contained (1) all main omic measurements (metabolomics, proteomics,
527 clinical laboratory tests) from the same first blood draw, (2) a BMI measurement within ± 1.5 month
528 from the first blood draw, and (3) genetic information (for using as covariates). We also eliminated (1)
529 outlier participants whose baseline BMI was beyond ± 3 s.d. from the mean in the baseline BMI
530 distribution and (2) participants whose any of omic datasets contained more than 10% missingness in
531 the filtered analytes (see the next section). The final Arivale cohort consisted of 1,277 (821 female and
532 456 male) participants (Fig. 1a), which exhibited consistent demographics (Supplementary Fig. 1a–c,
533 Supplementary Data 1) with the study cohorts defined in the previous Arivale studies^{20,25–29}. For the
534 analyses of gut microbiome, sub-cohort was defined with the 702 (486 female and 216 male)
535 participants from the Arivale cohort, who collected a stool sample within ± 1.5 month from the first
536 blood draw and did not use antibiotics in the last three months (Fig. 4a, Supplementary Data 1). For
537 longitudinal analyses, sub-cohort was defined with the 608 (410 female and 198 male) participants
538 from the Arivale cohort, whose datasets contained two or more time-series datasets for both BMI and
539 omics during 18 months after enrollment (Fig. 5a, Supplementary Data 1). For the analyses of waist-
540 to-height ratio (WHtR), sub-cohort was defined with the 1,078 (689 female and 389 male) participants
541 from the Arivale cohort, whose datasets contained the baseline WHtR measurement within ± 1.5
542 month from the first blood draw and within ± 3 s.d. from the mean in the baseline WHtR distribution
543 (Supplementary Fig. 7a, Supplementary Data 1).

544 The external cohort (TwinsUK cohort) was derived from 17,630 individuals who participated
545 in the TwinsUK Registry, a British national register of adult twins³¹. Twins were recruited as
546 volunteers by media campaigns without screening for any particular disease. The participants had two
547 or more clinical visits for biological sampling between 1992–2022. In the current study, to validate
548 our findings in the Arivale cohort, we limited the original cohort to the participants whose datasets
549 contained all measurements for metabolomics³², BMI, and the obesity-related standard clinical
550 measures (i.e., defined by triglycerides, high-density lipoprotein (HDL)-cholesterol, low-density
551 lipoprotein (LDL)-cholesterol, glucose, insulin, and homeostatic model assessment for insulin
552 resistance (HOMA-IR) throughout the current study) from the same visit. We also eliminated (1)
553 outlier participants whose BMI was beyond ± 3 s.d. from the mean in the overall BMI distribution and
554 (2) participants whose metabolomic dataset contained more than 10% missingness in the filtered
555 metabolites (see the next section). The final TwinsUK cohort consisted of 1,834 (1,774 female and 60
556 male) participants (Fig. 1a, Supplementary Fig. 1d–f, Supplementary Data 1). For the analyses of gut
557 microbiome, sub-cohort was defined with the 329 (307 female and 22 male) participants from the
558 TwinsUK cohort, who collected a stool sample within ± 1.5 month from the clinical visit and did not
559 use antibiotics at that time (Fig. 4a, Supplementary Data 1).

560 The current study was conducted with de-identified data of the participants who had
561 consented to the use of their anonymized data in research. All procedures were approved by the

562 Western Institutional Review Board (WIRB) with Institutional Review Board (IRB) (Study Number:
563 20170658 at Institute for Systems Biology and 1178906 at Arivale) and by the TwinsUK Resource
564 Executive Committee (TREC) (Project Number: E1192).
565

566 **Data collections and data cleaning**

567 Multiomics data for the Arivale participants included genomics and longitudinal measurements of
568 metabolomics, proteomics, clinical laboratory tests, gut microbiomes, wearable devices, and
569 health/lifestyle questionnaires. Peripheral venous blood draws for all measurements were performed
570 by trained phlebotomists at LabCorp (Laboratory Corporation of America Holdings, North Carolina,
571 USA) or Quest (Quest Diagnostics, New Jersey, USA) service centers. Saliva to measure analytes
572 such as diurnal cortisol and dehydroepiandrosterone (DHEA) was sampled by participants at home
573 using a standardized kit (ZRT Laboratory, Oregon, USA). Likewise, stool samples for gut microbiome
574 measurements were obtained by participants at home using a standardized kit (DNA Genotek, Inc.,
575 Ottawa, Canada).

576 – **Genomics**

577 DNA was extracted from each whole blood sample and underwent whole genome sequencing
578 (1,257 participants) or single-nucleotide polymorphisms (SNP) microarray genotyping (20
579 participants). Genetic ancestry was calculated with principal components (PCs) using a set of
580 ~100,000 ancestry-informative SNP markers, as described previously²⁵. Polygenic risk scores
581 (PRSs) were constructed using publicly available summary statistics from published genome-
582 wide association studies (GWAS), as described previously²⁷.
583

584 – **Blood-measured omics**

585 Metabolomics data was generated by Metabolon, Inc. (North Carolina, USA), using ultra-
586 high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) for
587 plasma derived from each whole blood sample. Proteomics data was generated using
588 proximity extension assay (PEA) for plasma derived from each whole blood sample with
589 several Olink Target panels (Olink Proteomics, Uppsala, Sweden), and only the
590 measurements with the Cardiovascular II, Cardiovascular III, and Inflammation panels were
591 used in the current study since the other panels were not necessarily applied to all samples.
592 All clinical laboratory tests were performed by LabCorp or Quest in a Clinical Laboratory
593 Improvement Amendments (CLIA)-certified lab, and only the measurements by LabCorp
594 were selected in the current study to eliminate potential differences between vendors. In the
595 current study, the batch-corrected datasets with in-house pipeline were used, and
596 metabolomic dataset was \log_e -transformed. In addition, analytes missing in more than 10% of
597 the baseline samples were removed from each omic dataset, and observations missing in more
598 than 10% of the remaining analytes were further removed. The final filtered metabolomics,
599 proteomics, and clinical labs consisted of 766 metabolites, 274 proteins, 71 clinical laboratory
600 tests, respectively (Supplementary Data 2).
601

602 – **Gut microbiome**

603 Gut microbiome data was generated based on 16S amplicon sequencing of the V3+V4 region
604 using a MiSeq sequencer (Illumina, Inc., California, USA) for DNA extracted from each stool
605 sample, as previously described²⁸. Briefly, the FASTQ files were processed using the mbtools
606 workflow (<https://github.com/Gibbons-Lab/mbtools>) to remove noise, infer amplicon
607 sequence variants (ASVs), and remove chimeras. Taxonomy assignment was performed using
608 the SILVA ribosomal RNA gene database (version 132)⁶⁴. In the current study, the final
609 collapsed ASV table across the samples consisted of 394, 341, 85, 45, 26, and 16 taxa for
610 species, genus, family, order, class, and phylum, respectively. Gut microbiome α -diversity

611 was calculated at the ASV level using Shannon's index calculated by $H = -\sum_{i=1}^S p_i \ln p_i$,
612 where p_i is the proportion of a community i represented by ASVs, or using Chao1 diversity
613 score calculated by $S_{\text{Chao1}} = S_{\text{obs}} + \frac{n_1^2}{2n_2}$, where S_{obs} is the number of observed ASVs, n_1 is the
614 number of singletons (ASVs captured once), and n_2 is the number of doubletons (ASVs
615 captured twice).
616

617 – Anthropometrics, saliva-measured analytes, and daily physical activity measures

618 Anthropometrics including weight, height, and waist circumference (WC) and blood pressure
619 were measured at the time of blood draw and also reported by participants, which generated
620 diverse timing and number of observations depending on each participant. BMI and WHtR
621 were simultaneously calculated from the measured anthropometrics with the weight divided
622 by squared height [kg m^{-2}] and the WC divided by height [unitless], respectively.
623 Measurements of saliva samples were performed in the testing laboratory of ZRT Laboratory.
624 Daily physical activity measures such as heart rate, moving distance, step count, burned
625 calories, floors climbed, and sleep quality were tracked using the Fitbit wearable device
626 (Fitbit, Inc., California, USA). To manage variations between days, monthly averaged data
627 was used for these daily measures. In the current study, the baseline measurement for these
628 longitudinal measures was defined with the closest observation to the first blood draw per
629 participant and data type, and each dataset was eliminated from analyses when its baseline
630 measurement was beyond ± 1.5 month from the first blood draw.

631 Data resource for the TwinsUK participants included longitudinal measurements of metabolomics,
632 clinical laboratory tests, dual-energy X-ray absorptiometry (DXA), and health/lifestyle
633 questionnaires³¹. The necessary datasets for the current study were provided by Department of Twin
634 Research & Genetic Epidemiology (King's College London). In the current study, after each provided
635 dataset was cleaned as follows, the earliest visit among the visits from which all of metabolomics,
636 BMI, and the standard clinical measures had been measured was defined as the baseline visit for each
637 participant. As exception, the later visit among them was prioritized as the baseline visit, if the
638 participant had gut microbiome data within ± 1.5 month from the visit. Only the baseline visit
639 measurements were analyzed.

640 – Blood-measured metabolomics

641 Metabolomics data was originally generated by Metabolon, Inc., using UHPLC-MS/MS for
642 each serum sample³². In the current study, the provided median-normalized dataset was \log_e -
643 transformed. In addition, metabolites missing in more than 10% of the overall samples were
644 removed from metabolomic dataset, and observations missing in more than 10% of the
645 remaining metabolites were further removed. The final filtered metabolomics consisted of
646 683 metabolites.
647

648 – BMI

649 In the current study, the BMI values that had been already calculated and included in the
650 provided metabolomics data file were used.
651

652 – Standard clinical measures and other phenotypic measures

653 In the current study, because the provided phenotypic datasets contained multiple
654 measurements for a phenotype even from a single visit of a participant (e.g., due to project
655 difference, repeated measurements), multiple measurements were flattened into a single
656 measurement for a phenotype per each participant's visit by taking the mean value. During
657 this flattening step, difference in unit was properly adjusted, and the value indicating below
658 detection limit was regarded as zero. HOMA-IR was calculated from the datasets of glucose,

659 insulin, and fasting condition with the formula: HOMA-IR = fasting glucose [mmol L⁻¹] ×
660 fasting insulin [mIU L⁻¹] × 22.5⁻¹.
661

662 – Gut microbiome

663 Gut microbiome data was originally generated based on whole metagenomic shotgun
664 sequencing (WMGS) using a HiSeq 2500 sequencer (Illumina, Inc.) for DNA extracted from
665 each stool sample⁴⁵. In the current study, the raw sequencing data was obtained from the
666 National Center for Biotechnology Information (NCBI) Sequence Read Archive (SRA)
667 project (PRJEB32731), and applied to a processing pipeline ([https://github.com/Gibbons-
668 Lab/pipelines](https://github.com/Gibbons-Lab/pipelines)). Briefly, the obtained FASTQ files were processed using the fastp (version
669 0.23.2) tool⁶⁵ to filter and trim the reads, and taxonomic abundance was obtained using the
670 Kraken 2 (version 2.1.2) and Bracken (version 2.6.0) tools⁶⁶ with the Kraken 2 default
671 database (based on NCBI RefSeq). The final collapsed taxonomic table across the samples
672 consisted of 4,669, 1,225, 354, 167, 76, and 35 taxa for species, genus, family, order, class,
673 and phylum, respectively.
674

675 Blood omics-based BMI and WHtR models

676 For each Arivale baseline omic dataset, missing values were first imputed with a random forest (RF)
677 algorithm using Python missingpy (version 0.2.0) library (corresponding to R MissForrest package⁶⁷).
678 For sex-stratified models (Supplementary Fig. 2d), the datasets after imputation were divided into sex-
679 stratified datasets. Subsequently, the values in each omic dataset were standardized with Z-score using
680 the mean and s.d. per analyte. Then, ten iterations of least absolute shrinkage and selection operator
681 (LASSO) modeling with tenfold cross-validation (CV) (Fig. 1a, Supplementary Fig. 7a) were
682 performed for the (unstandardized) log_e-transformed BMI or WHtR and each processed omic dataset,
683 using *LassoCV* application programming interface (API) of Python scikit-learn (version 1.0.1) library.
684 Training and testing (hold-out) sets were generated by splitting participants into ten sets with one set
685 as a testing (hold-out) set and the remaining nine sets as a training set, and iterating all combinations
686 over those ten sets; i.e., overfitting was controlled using tenfold iteration with ten testing (hold-out)
687 sets, and hyperparameter was decided using tenfold CV with internal training and validation sets from
688 each training set. Consequently, this procedure generated ten fitted sparse models for each omics
689 category (Supplementary Data 3) and one single testing (hold-out) set-derived prediction from each
690 omics category for each participant. The same modeling scheme while replacing LASSO with elastic
691 net (EN), ridge, or RF was performed using Python scikit-learn *ElasticNetCV*, *RidgeCV*, or
692 *RandomForestRegressor*-implemented *GridSearchCV* API, respectively. In this RF-modeling, the
693 number of trees in the forest and the number of features were set as the hyperparameters to be decided
694 through CV. For the standard measures-based models, the above modeling scheme was applied to
695 ordinary least squares (OLS) linear regression with sex, age, triglycerides, HDL-cholesterol, LDL-
696 cholesterol, glucose, insulin, and HOMA-IR as regressors, using Python scikit-learn *LinearRegression*
697 API. Of note, ten split sets were fixed among the omics categories and the modeling methods, and no
698 significant difference in BMI, WHtR, sex, age, and ancestry PC1–5 among those ten sets was
699 confirmed, using Pearson's χ^2 test for categorical variable and Analysis of Variance (ANOVA) for
700 numeric variable while adjusting multiple testing with the Benjamini–Hochberg method across the
701 tested variables (Supplementary Data 1).

702 For the TwinsUK cohort, metabolomic dataset was applied to RF imputation and then each
703 dataset of metabolomics and the standard clinical measures was applied to Z-score standardization, as
704 well as the Arivale datasets. Utilizing the ten LASSO or OLS linear regression models that were fitted
705 by the Arivale dataset, one single prediction was calculated from each processed dataset for each
706 participant by taking the mean of ten predicted values. For metabolomics, ten metabolomics-based
707 BMI (MetBMI) models were regenerated while restricting the input Arivale metabolomics to the
708 common 489 metabolites in the Arivale and TwinsUK panels (Supplementary Fig. 3).

709 For the LASSO-modeling iteration analysis (Supplementary Fig. 2e–h, 7f–i), ten LASSO
710 models were repeatedly generated with the above modeling scheme. At the end of each iteration, the
711 variable that was retained across ten models and that had the highest absolute value for the mean of
712 ten β -coefficients was removed from the input omic dataset.

713 For longitudinal predictions of the Arivale sub-cohort, one single prediction at a time point
714 was calculated from each processed time-series omic dataset for each participant, utilizing the baseline
715 LASSO model for which the participant was included in the baseline testing (hold-out) set. This was
716 because (1) the baseline measurements were minimally affected by the personalized lifestyle
717 coaching, (2) both count and time point of data collections were different among the participants, and
718 (3) potential data leakage might be derived from the relationships between the baseline and following
719 measurements for the same participant. For processing, each time-series omic dataset was applied to
720 two-step RF imputation, where the baseline missingness was first imputed based on the baseline data
721 structure and the remaining missingness was next imputed based on the overall data structure, and
722 subsequently applied to Z-score standardization using the mean and s.d. in the baseline distribution.

723 Model performance was conservatively evaluated by the out-of-sample R^2 that was calculated
724 from each corresponding hold-out testing set in the Arivale cohort or from the external testing set in
725 the TwinsUK cohort. Pearson's r between the measured and predicted values was calculated from the
726 overall participants of the Arivale or TwinsUK cohort. Difference of the predicted value from the
727 measured value (Δ Measure; i.e., Δ BMI or Δ WhtR) was calculated with (the predicted value – the
728 measured value) \times (the measured value) $^{-1} \times 100$ (i.e., the unit of Δ Measure was [% Measure]). In the
729 RF model, the importance of a feature was calculated as the normalized total reduction of the mean
730 squared error that was brought by the feature.

732 **Health classification**

733 Each participant was classified using each of the measured and omics-inferred BMIs based on the
734 World Health Organization (WHO) international standards for BMI cutoffs (underweight: $<18.5 \text{ kg}$
735 m^{-2} , normal: $18.5\text{--}25 \text{ kg m}^{-2}$, overweight: $25\text{--}30 \text{ kg m}^{-2}$, obese: $\geq 30 \text{ kg m}^{-2}$)¹². For the
736 misclassification of BMI class against the omics-inferred BMI class, each participant was categorized
737 into either Matched or Mismatched group when the measured BMI class was matched or mismatched
738 to each omics-inferred BMI class, respectively.

739 For a clinically-defined metabolic health classification, the participants having two or more
740 metabolic syndrome (MetS) risks of the National Cholesterol Education Program (NCEP) Adult
741 Treatment Panel III (ATP III) guidelines were judged as the metabolically unhealthy group, while the
742 other participants were judged as the metabolically healthy group^{34,35}. Concretely, the MetS risk
743 components were (1) systolic blood pressure $\geq 130 \text{ mm Hg}$, diastolic blood pressure $\geq 85 \text{ mm Hg}$, or
744 using antihypertensive medication, (2) fasting triglyceride level $\geq 150 \text{ mg dL}^{-1}$, (3) fasting HDL-
745 cholesterol level $< 50 \text{ mg dL}^{-1}$ for female and $< 40 \text{ mg dL}^{-1}$ for male or using lipid-lowering
746 medication, and (4) fasting glucose level $\geq 100 \text{ mg dL}^{-1}$ or using antidiabetic medication. Only the
747 participants who had all these information were assessed in the corresponding analyses (Fig. 3b;
748 Supplementary Fig. 6a, 7m).

750 **Gut microbiome-based models for classifying obesity**

751 For the Arivale gut microbiome dataset, the whole ASV table (907 taxa from species to phylum) was
752 preprocessed (i.e., positively shifted by one, \log_e -transformed, and standardized with Z-score using the
753 mean and s.d. per taxon) and then applied to dimensionality reduction using PCA API of Python
754 scikit-learn (version 1.0.1) library; the projected values onto the first 50 PCs (0.4–5.1% variance
755 explained) were supplied as the input gut microbiome features. Two types of classifiers were trained
756 on these gut microbiome features: one predicting whether an individual is obese BMI class and the
757 other predicting whether an individual is obese MetBMI class. Both models were independently
758 constructed through a fivefold iteration scheme of RF with fivefold CV (Fig. 4a), using Python scikit-

759 learn *RandomForestClassifier*-implemented *GridSearchCV* API. In this RF-modeling, the number of
760 trees in the forest and the number of features were set as the hyperparameters to be decided through
761 CV. Training and testing (hold-out) sets were generated by splitting the participants of the normal and
762 obese classes into five sets with one set as a testing (hold-out) set and the remaining four sets as a
763 training set, and iterating all combinations over those five sets; i.e., overfitting was controlled using
764 fivefold iteration with five testing (hold-out) sets, and hyperparameters were decided using fivefold
765 CV with internal training and validation sets from each training set. Consequently, this procedure
766 generated five fitted classifiers for each BMI or MetBMI class and one single testing (hold-out) set-
767 derived prediction from each classifier type for each participant. Note that this prediction included two
768 types: either normal or obese class by a vote of the trees (i.e., binary prediction) and the mean
769 probability of obese class among the trees.

770 For the TwinsUK gut microbiome dataset, the whole taxonomic table (6,526 taxa from
771 species to phylum) was preprocessed and then applied to dimensionality reduction, as well as the
772 Arivale dataset; the projected values onto the first 50 PCs (0.2–40.1% variance explained) were
773 supplied as the input gut microbiome features. Then, the five obesity classifiers for each BMI or
774 MetBMI class were generated as well as the above Arivale procedure, and one single testing (hold-
775 out) set-derived prediction from each classifier type was calculated for each participant (Fig. 4a).

776 Model performance of each classifier was conservatively evaluated using each corresponding
777 hold-out testing set. Area under curve (AUC) in the receiver operator characteristic (ROC) curve and
778 the average precision were calculated using the probability predictions, while sensitivity and
779 specificity were calculated from confusion matrix using the binary predictions. The overall ROC
780 curve and its AUC was calculated from all the participant's probability predictions, using R pROC
781 (version 1.18.0) package⁶⁸.

782

783 **Longitudinal changes in the measured and omics-inferred BMIs**

784 A linear mixed model (LMM) was generated for each \log_e -transformed measured or omics-inferred
785 BMI in the Arivale sub-cohort, following the previous approach²⁵. As fixed effects regarding time,
786 linear regression splines with knots at 0, 6, 12, and 18 months were applied to days in program to fit
787 time as a continuous variable rather than a categorical variable, because both count and time point of
788 data collections were different among the participants. In addition to the linear regression splines of
789 time as fixed effects, the LMM included sex, baseline age, ancestry PC1–5, and meteorological
790 seasons as fixed effects (to adjust potential confounding effects) and random intercepts and random
791 slopes of days in the program as random effects for each participant. Additionally, the same LMM for
792 each measured or omics-inferred BMI was independently generated from each baseline BMI class-
793 stratified group. Of note, this stratified LMM was not generated from the underweight group because
794 its sample size was too small for convergence. For comparing difference between the misclassification
795 strata against the baseline MetBMI class, the above LMM while adding additional fixed effects, the
796 categorical baseline misclassification of BMI class against MetBMI class (i.e., binary for Matched vs.
797 Mismatched) and its interaction terms with the linear regression splines of time, was generated for
798 each measured BMI or MetBMI from each baseline BMI class-stratified group. All LMMs were
799 modeled using *MixedLM* API of Python statsmodels (version 0.13.0) library.

800

801 **Plasma analyte correlation network analysis**

802 Prior to the analysis, outlier values which were beyond ± 3 s.d. from the mean in the Arivale sub-
803 cohort baseline distribution were eliminated from the dataset per analyte, and seven clinical laboratory
804 tests which became almost invariant across the participants were eliminated from analyses, allowing
805 convergence in the following modeling. Per each analyte, values were converted with a transformation
806 pipeline producing the lowest skewness (e.g., no transformation, the logarithm transformation for right
807 skewed distribution, the square root transformation with mirroring for left skewed distribution) and
808 standardized with *Z*-score using the mean and s.d.

809 Against 608,856 pairwise combinations of the analytes (766 metabolites, 274 proteomics, 64
810 clinical laboratory tests), generalized linear models (GLMs) for the baseline measurements of the
811 Arivale sub-cohort (Fig. 5a; 608 participants) were independently generated with the Gaussian
812 distribution and identity link function using *glm* API of Python statsmodels (version 0.13.0) library.
813 Each GLM consisted of an analyte as dependent variable, another analyte and the baseline MetBMI as
814 independent variables with their interaction term, and sex, baseline age, and ancestry PC1–5 as
815 covariates. The analyte–analyte correlation pair that was significantly modified by the baseline
816 MetBMI was obtained based on the β -coefficient (two-sided *t*-test) of the interaction term between the
817 independent variables in GLM, while adjusting multiple testing with the Benjamini–Hochberg method
818 (false discovery rate (FDR) < 0.05).

819 Against the significant 100 pairs from the GLM analysis (82 metabolites, 33 proteins, and 16
820 clinical laboratory tests; Supplementary Data 7), generalized estimating equations (GEEs) for the
821 longitudinal measurements of the metabolically obese group (i.e., the baseline obese MetBMI class;
822 182 participants) were independently generated with the exchangeable covariance structure using
823 Python statsmodels *GEE* API. Each GEE consisted of an analyte as dependent variable, another
824 analyte and days in the program as independent variables with their interaction term, and sex, baseline
825 age, ancestry PC1–5, and meteorological seasons as covariates. The analyte–analyte correlation pair
826 that was significantly modified by days in the program was obtained based on the β -coefficient (two-
827 sided *t*-test) of the interaction term between the independent variables in GEE, while adjusting
828 multiple testing with the Benjamini–Hochberg method (FDR < 0.05).
829

830 **Statistical analysis**

831 All data preprocessing and statistical analyses were performed using Python NumPy (version 1.18.1 or
832 1.21.3), pandas (version 1.0.3 or 1.3.4), SciPy (version 1.4.1 or 1.7.1) and statsmodels (version 0.11.1
833 or 0.13.0) libraries, except for using R pROC (version 1.18.0) package⁶⁸ for DeLong’s test⁶⁹. All
834 statistical tests were performed using a two-sided hypothesis. In all cases of multiple testing, *P*-value
835 was adjusted with the Benjamini–Hochberg method. Of note, because some hypotheses were not
836 completely independent (e.g., between combined omics and each individual omics; between glucose,
837 insulin, and HOMA-IR), this simple *P*-value adjustment was regarded as a conservative approach.
838 Significance was based on *P* < 0.05 for single testing and FDR < 0.05 for multiple testing. Test
839 summaries (e.g., sample size, degrees of freedom, test statistic, exact *P*-value) are found in
840 Supplementary Data 4, 5, 6, 9, and 10.

841 Correlations (Fig. 1b, 3a; Supplementary Fig. 3b–d, 4b, 4f, 7c, 7d, 7l, 8d, 8e) were
842 independently assessed using Pearson’s correlation test (Python SciPy *pearsonr* API), with the *P*-
843 value adjustment if multiple testing. Comparisons of model performance (Fig. 1c, 1d, 4d, 4f;
844 Supplementary Fig. 2d, 4a, 7e) were independently assessed using Welch’s *t*-test (Python statsmodels
845 *ttest_ind* API), with the *P*-value adjustment if multiple testing. Comparison of overall ROC curves
846 (Fig. 4c, 4e) was assessed using unpaired DeLong’s test⁶⁹.

847 In all regression analyses, only the baseline datasets were used, and, unless otherwise
848 specified, all numeric variables were centered and scaled in advance. For the Arivale datasets of
849 anthropometrics, saliva-measured analytes, daily physical activity measures, and PRSs, (1) outlier
850 values which were beyond ± 3 s.d. from the mean in the cohort distribution were eliminated from the
851 dataset per variable, (2) variables which became almost invariant across the participants were
852 eliminated from the datasets, (3) values were converted with a transformation pipeline producing the
853 lowest skewness (e.g., no transformation, the logarithm transformation for right skewed distribution,
854 the square root transformation with mirroring for left skewed distribution), and (4) the transformed
855 values were standardized with *Z*-score using the mean and s.d.; these preprocessed 51 variables were
856 used as the numeric physiological features (Supplementary Data 4). Likewise, the Arivale datasets of
857 the obesity-related clinical blood markers (i.e., selected clinical labs; Supplementary Data 6) and the
858 TwinsUK datasets of the obesity-related phenotypic measures (Supplementary Data 6) were
859 preprocessed. For gut microbiome α -diversity metrics, the number of observed ASVs and Chao1

860 index were converted with square root transformation while Shannon's index was converted with
861 square transformation, and then these transformed values were standardized with Z-score using the
862 mean and s.d. Relationships of the numeric physiological features with the measured or omics-inferred
863 BMI (Fig. 1e) were independently assessed using each OLS linear regression model with the
864 (unstandardized) \log_e -transformed measured or omics-inferred BMI as dependent variable, a feature as
865 independent variable, and sex, age, and ancestry PC1–5 as covariates, while adjusting multiple testing
866 across the 255 (51 features \times 5 BMI types) regressions. Relationships between Measure (i.e., BMI or
867 WHtR) and the analytes that were retained in at least one of ten LASSO models (Fig. 2b–d,
868 Supplementary Fig. 7k) were independently assessed using each OLS linear regression model with the
869 (unstandardized) \log_e -transformed Measure as dependent variable, an analyte as independent variable,
870 and sex, age, and ancestry PC1–5 as covariates, while adjusting multiple testing across the 210 (Fig.
871 2b), 75 (Fig. 2c), 42 (Fig. 2d), or 289 (Supplementary Fig. 7k) regressions. In this regression analysis,
872 a model including the omics-inferred Measure as independent variable was also assessed as reference.
873 Differences in Δ Measure (i.e., Δ BMI or Δ WHtR) between clinically-defined metabolic health
874 conditions (Fig. 3b; Supplementary Fig. 6a, 7m) were independently assessed using each OLS linear
875 regression model with Δ Measure as dependent variable, metabolic condition (i.e., Healthy vs.
876 Unhealthy) as categorical independent variable, and Measure, sex, age, and ancestry PC1–5 as
877 covariates, while adjusting multiple testing across the eight (two BMI classes \times four omics categories;
878 Fig. 3b, Supplementary Fig. 7m) or four (two BMI classes \times two cohorts; Supplementary Fig. 6a)
879 regressions. Differences in the obesity-related clinical blood markers, the BMI-associated numeric
880 physiological features, or the gut microbiome α -diversity metrics between the misclassification strata
881 against the omics-inferred BMI class (Fig. 3d, 3e, 4b; Supplementary Fig. 6c) were independently
882 assessed using each OLS linear regression model with a marker, feature, or metric as dependent
883 variable, misclassification (i.e., Matched vs. Mismatched) as categorical independent variable, and
884 BMI, sex, age, and ancestry PC1–5 as covariates, while adjusting multiple testing across the 40 (2
885 BMI classes \times 2 omics categories \times 10 markers; Fig. 3d), 216 (2 BMI classes \times 4 omics categories \times
886 27 features; Fig. 3e), 24 (2 BMI classes \times 4 omics categories \times 3 metrics; Fig. 4b), or 24 (2 BMI
887 classes \times 12 measures; Supplementary Fig. 6c) regressions. In the above regression analyses for the
888 TwinsUK cohort, ancestry PCs were eliminated from the covariates due to data availability.
889

890 Data visualization

891 Results were visualized using Python matplotlib (version 3.4.3) and seaborn (version 0.11.2) libraries,
892 except for the plasma analyte correlation network. Data were summarized as the mean with 95%
893 confidence interval (CI) or the boxplot (median: center line; 95% CI around median: notch; $[Q_1, Q_3]$:
894 box limits; $[x_{\min}, x_{\max}]$: whiskers, where Q_1 and Q_3 are the 1st and 3rd quartile values, and x_{\min} and x_{\max}
895 are the minimum and maximum values in $[Q_1 - 1.5 \times \text{IQR}, Q_3 + 1.5 \times \text{IQR}]$ (IQR: the interquartile
896 range, $Q_3 - Q_1$), respectively), as indicated in each figure legend. For presentation purpose, CI was
897 simultaneously calculated during visualization using Python seaborn *barplot* or *boxplot* API with
898 default setting (1,000 times bootstrapping or a Gaussian-based asymptotic approximation,
899 respectively). The OLS linear regression line with 95% CI was simultaneously generated during
900 visualization using Python seaborn *regplot* API with default setting (1,000 times bootstrapping). The
901 plasma analyte correlation network was visualized with a circo plot using R circlize (version 0.4.15)
902 package⁷⁰.
903

904 Data availability

905 The de-identified Arivale datasets that were used in this study can be accessed by qualified researchers
906 for research purposes. Requests should be sent to data-access@isbscience.org, and the data will be
907 available after submission and approval of a research plan. The de-identified TwinsUK datasets that
908 were used in this study were provided by Department of Twin Research & Genetic Epidemiology
909 (King's College London) after the approval of our Data Access Application (Project Number: E1192).

910 Requests should be referred to their website ([http://twinsuk.ac.uk/resources-for-researchers/access-](http://twinsuk.ac.uk/resources-for-researchers/access-our-data/)
911 [our-data/](http://twinsuk.ac.uk/resources-for-researchers/access-our-data/)).

912

913 **Code availability**

914 Code used in this study is freely available on GitHub (<https://github.com/PriceLab/Multiomics-BMI>).

915

916 **References**

917 1. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975
918 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants.
919 *Lancet (London, England)* **387**, 1377–1396 (2016).

920 2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight,
921 overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement
922 studies in 128·9 million children, adolescents, and adults. *Lancet (London, England)* **390**, 2627–2642
923 (2017).

924 3. Kopelman, P. G. Obesity as a medical problem. *Nature* **404**, 635–43 (2000).

925 4. Haslam, D. W. & James, W. P. T. Obesity. *Lancet (London, England)* **366**, 1197–209 (2005).

926 5. Kahn, S. E., Hull, R. L. & Utzschneider, K. M. Mechanisms linking obesity to insulin resistance and type 2
927 diabetes. *Nature* **444**, 840–6 (2006).

928 6. Van Gaal, L. F., Mertens, I. L. & De Block, C. E. Mechanisms linking obesity with cardiovascular disease.
929 *Nature* **444**, 875–80 (2006).

930 7. Magkos, F. *et al.* Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and
931 Adipose Tissue Biology in Humans with Obesity. *Cell Metab.* **23**, 591–601 (2016).

932 8. Hamman, R. F. *et al.* Effect of weight loss with lifestyle intervention on risk of diabetes. *Diabetes Care* **29**,
933 2102–7 (2006).

934 9. Sun, Q. *et al.* Comparison of dual-energy x-ray absorptiometric and anthropometric measures of adiposity in
935 relation to adiposity-related biologic factors. *Am. J. Epidemiol.* **172**, 1442–54 (2010).

936 10. Prentice, A. M. & Jebb, S. A. Beyond body mass index. *Obes. Rev.* **2**, 141–7 (2001).

937 11. Okorodudu, D. O. *et al.* Diagnostic performance of body mass index to identify obesity as defined by body
938 adiposity: A systematic review and meta-analysis. *Int. J. Obes.* **34**, 791–799 (2010).

939 12. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for
940 policy and intervention strategies. *Lancet (London, England)* **363**, 157–63 (2004).

941 13. Ruderman, N., Chisholm, D., Pi-Sunyer, X. & Schneider, S. The metabolically obese, normal-weight
942 individual revisited. *Diabetes* **47**, 699–713 (1998).

943 14. Ding, C., Chan, Z. & Magkos, F. Lean, but not healthy: the ‘metabolically obese, normal-weight’
944 phenotype. *Curr. Opin. Clin. Nutr. Metab. Care* **19**, 408–417 (2016).

945 15. Smith, G. I., Mittendorfer, B. & Klein, S. Metabolically healthy obesity: facts and fantasies. *J. Clin. Invest.*
946 **129**, 3978–3989 (2019).

947 16. Appleton, S. L. *et al.* Diabetes and cardiovascular disease outcomes in the metabolically healthy obese
948 phenotype: a cohort study. *Diabetes Care* **36**, 2388–94 (2013).

949 17. Schröder, H. *et al.* Determinants of the transition from a cardiometabolic normal to abnormal
950 overweight/obese phenotype in a Spanish population. *Eur. J. Nutr.* **53**, 1345–53 (2014).

951 18. Williams, S. A. *et al.* Plasma protein patterns as comprehensive indicators of health. *Nat. Med.* **25**, 1851–
952 1857 (2019).

953 19. Bar, N. *et al.* A reference map of potential determinants for the human serum metabolome. *Nature* **588**, 135–
954 140 (2020).

955 20. Wilmanski, T. *et al.* Blood metabolome predicts gut microbiome α -diversity in humans. *Nat. Biotechnol.* **37**,
956 1217–1228 (2019).

957 21. Cirulli, E. T. *et al.* Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. *Cell*
958 *Metab.* **29**, 488–500.e2 (2019).

959 22. Talmor-Barkan, Y. *et al.* Metabolomic and microbiome profiling reveals personalized risk factors for
960 coronary artery disease. *Nat. Med.* **28**, 295–302 (2022).

961 23. Nimptsch, K., Konigorski, S. & Pischon, T. Diagnosis of obesity and use of obesity biomarkers in science
962 and clinical medicine. *Metabolism.* **92**, 61–70 (2019).

963 24. Price, N. D. *et al.* A wellness study of 108 individuals using personal, dense, dynamic data clouds. *Nat.*
964 *Biotechnol.* **35**, 747–756 (2017).

965 25. Zubair, N. *et al.* Genetic Predisposition Impacts Clinical Changes in a Lifestyle Coaching Program. *Sci. Rep.*
966 **9**, 6805 (2019).

967 26. Earls, J. C. *et al.* Multi-Omic Biological Age Estimation and Its Correlation With Wellness and Disease
968 Phenotypes: A Longitudinal Study of 3,558 Individuals. *J. Gerontol. A. Biol. Sci. Med. Sci.* **74**, S52–S60
969 (2019).

970 27. Wainberg, M. *et al.* Multiomic blood correlates of genetic risk identify presymptomatic disease alterations.
971 *Proc. Natl. Acad. Sci. U. S. A.* **117**, 21813–21820 (2020).

- 972 28. Wilmanski, T. *et al.* Gut microbiome pattern reflects healthy ageing and predicts survival in humans. *Nat.*
973 *Metab.* **3**, 274–286 (2021).
- 974 29. Zimmer, A. *et al.* The geometry of clinical labs and wellness states from deeply phenotyped humans. *Nat.*
975 *Commun.* **12**, 3578 (2021).
- 976 30. Tibshirani, R. Regression Shrinkage and Selection Via the Lasso. *J. R. Stat. Soc. Ser. B* **58**, 267–288 (1996).
- 977 31. Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort Profile: TwinsUK and healthy
978 ageing twin study. *Int. J. Epidemiol.* **42**, 76–85 (2013).
- 979 32. Long, T. *et al.* Whole-genome sequencing identifies common-to-rare variants associated with human blood
980 metabolites. *Nat. Genet.* **49**, 568–578 (2017).
- 981 33. Xu, X. *et al.* Habitual sleep duration and sleep duration variation are independently associated with body
982 mass index. *Int. J. Obes. (Lond).* **42**, 794–800 (2018).
- 983 34. Stefan, N., Schick, F. & Häring, H.-U. Causes, Characteristics, and Consequences of Metabolically
984 Unhealthy Normal Weight in Humans. *Cell Metab.* **26**, 292–300 (2017).
- 985 35. Blüher, M. Metabolically Healthy Obesity. *Endocr. Rev.* **41**, 405–420 (2020).
- 986 36. Shah, N. R. & Braverman, E. R. Measuring adiposity in patients: the utility of body mass index (BMI),
987 percent body fat, and leptin. *PLoS One* **7**, e33308 (2012).
- 988 37. Tomiyama, A. J., Hunger, J. M., Nguyen-Cuu, J. & Wells, C. Misclassification of cardiometabolic health
989 when using body mass index categories in NHANES 2005–2012. *Int. J. Obes. (Lond).* **40**, 883–6 (2016).
- 990 38. Bennett, C. M., Guo, M. & Dharmage, S. C. HbA(1c) as a screening tool for detection of Type 2 diabetes: a
991 systematic review. *Diabet. Med.* **24**, 333–43 (2007).
- 992 39. Pereira-Santos, M., Costa, P. R. F., Assis, A. M. O., Santos, C. A. S. T. & Santos, D. B. Obesity and vitamin
993 D deficiency: a systematic review and meta-analysis. *Obes. Rev.* **16**, 341–9 (2015).
- 994 40. Ridaura, V. K. *et al.* Gut microbiota from twins discordant for obesity modulate metabolism in mice.
995 *Science* **341**, 1241214 (2013).
- 996 41. Turnbaugh, P. J. *et al.* A core gut microbiome in obese and lean twins. *Nature* **457**, 480–484 (2009).
- 997 42. Le Chatelier, E. *et al.* Richness of human gut microbiome correlates with metabolic markers. *Nature* **500**,
998 541–546 (2013).
- 999 43. Walters, W. A., Xu, Z. & Knight, R. Meta-analyses of human gut microbes associated with obesity and IBD.
1000 *FEBS Lett.* **588**, 4223–4233 (2014).
- 1001 44. Duvallet, C., Gibbons, S. M., Gurry, T., Irizarry, R. A. & Alm, E. J. Meta-analysis of gut microbiome
1002 studies identifies disease-specific and shared responses. *Nat. Commun.* **8**, 1784 (2017).
- 1003 45. Visconti, A. *et al.* Interplay between the human gut microbiome and host metabolism. *Nat. Commun.* **10**,
1004 4505 (2019).
- 1005 46. Diener, C. *et al.* Baseline Gut Metagenomic Functional Gene Signature Associated with Variable Weight
1006 Loss Responses following a Healthy Lifestyle Intervention in Humans. *mSystems* **6**, e0096421 (2021).
- 1007 47. Karetnikova, E. S. *et al.* Is Homoarginine a Protective Cardiovascular Risk Factor? *Arterioscler. Thromb.*
1008 *Vasc. Biol.* **39**, 869–875 (2019).
- 1009 48. Dieuleveux, V., Lemarinier, S. & Guéguen, M. Antimicrobial spectrum and target site of D-3-phenyllactic
1010 acid. *Int. J. Food Microbiol.* **40**, 177–83 (1998).
- 1011 49. Beloborodova, N. *et al.* Effect of phenolic acids of microbial origin on production of reactive oxygen
1012 species in mitochondria and neutrophils. *J. Biomed. Sci.* **19**, 89 (2012).
- 1013 50. Després, J.-P. & Lemieux, I. Abdominal obesity and metabolic syndrome. *Nature* **444**, 881–7 (2006).
- 1014 51. Ashwell, M., Gunn, P. & Gibson, S. Waist-to-height ratio is a better screening tool than waist circumference
1015 and BMI for adult cardiometabolic risk factors: systematic review and meta-analysis. *Obes. Rev.* **13**, 275–86
1016 (2012).
- 1017 52. Swainson, M. G., Batterham, A. M., Tsakirides, C., Rutherford, Z. H. & Hind, K. Prediction of whole-body
1018 fat percentage and visceral adipose tissue mass from five anthropometric variables. *PLoS One* **12**, e0177175
1019 (2017).
- 1020 53. Li, Y. *et al.* Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues.
1021 *Peptides* **28**, 1129–43 (2007).
- 1022 54. Egaña-Gorroño, L. *et al.* Receptor for Advanced Glycation End Products (RAGE) and Mechanisms and
1023 Therapeutic Opportunities in Diabetes and Cardiovascular Disease: Insights From Human Subjects and
1024 Animal Models. *Front. Cardiovasc. Med.* **7**, 37 (2020).
- 1025 55. Norata, G. D. *et al.* Circulating soluble receptor for advanced glycation end products is inversely associated
1026 with body mass index and waist/hip ratio in the general population. *Nutr. Metab. Cardiovasc. Dis.* **19**, 129–
1027 34 (2009).

- 1028 56. Rauschert, S., Uhl, O., Koletzko, B. & Hellmuth, C. Metabolomic biomarkers for obesity in humans: A
1029 short review. *Ann. Nutr. Metab.* **64**, 314–324 (2014).
- 1030 57. Rangel-Huerta, O. D., Pastor-Villaescusa, B. & Gil, A. Are we close to defining a metabolomic signature of
1031 human obesity? A systematic review of metabolomics studies. *Metabolomics* **15**, 93 (2019).
- 1032 58. Barber, M. N. *et al.* Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. *PLoS*
1033 *One* **7**, e41456 (2012).
- 1034 59. Piening, B. D. *et al.* Integrative Personal Omics Profiles during Periods of Weight Gain and Loss. *Cell Syst.*
1035 **6**, 157–170.e8 (2018).
- 1036 60. Koenig, R. J. *et al.* Correlation of glucose regulation and hemoglobin A1c in diabetes mellitus. *N. Engl. J.*
1037 *Med.* **295**, 417–20 (1976).
- 1038 61. Wing, R. R. & Phelan, S. Long-term weight loss maintenance. *Am. J. Clin. Nutr.* **82**, 222S–225S (2005).
- 1039 62. Li, G. *et al.* The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes
1040 Prevention Study: a 20-year follow-up study. *Lancet (London, England)* **371**, 1783–9 (2008).
- 1041 63. Diabetes Prevention Program Research Group *et al.* 10-year follow-up of diabetes incidence and weight loss
1042 in the Diabetes Prevention Program Outcomes Study. *Lancet (London, England)* **374**, 1677–86 (2009).
- 1043 64. Yilmaz, P. *et al.* The SILVA and ‘All-species Living Tree Project (LTP)’ taxonomic frameworks. *Nucleic*
1044 *Acids Res.* **42**, D643–8 (2014).
- 1045 65. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. *Bioinformatics*
1046 **34**, i884–i890 (2018).
- 1047 66. Lu, J. *et al.* Metagenome analysis using the Kraken software suite. *Nat. Protoc.* 1–25 (2022).
1048 doi:10.1038/s41596-022-00738-y
- 1049 67. Stekhoven, D. J. & Bühlmann, P. Missforest-Non-parametric missing value imputation for mixed-type data.
1050 *Bioinformatics* **28**, 112–118 (2012).
- 1051 68. Robin, X. *et al.* pROC: an open-source package for R and S+ to analyze and compare ROC curves. *BMC*
1052 *Bioinformatics* **12**, 77 (2011).
- 1053 69. DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated
1054 receiver operating characteristic curves: a nonparametric approach. *Biometrics* **44**, 837–45 (1988).
- 1055 70. Gu, Z., Gu, L., Eils, R., Schlesner, M. & Brors, B. Circlize implements and enhances circular visualization
1056 in R. *Bioinformatics* **30**, 2811–2812 (2014).
- 1057

1058 **Acknowledgements**

1059 We thank Sergey A. Kornilov, Gustavo Glusman, and Max Robinson (Institute for Systems Biology;
1060 ISB) for providing comments to this study. We thank Victoria Vazquez and Andrew Anastasiou
1061 (King's College London) for their support in obtaining and utilizing the TwinsUK data access. We are
1062 grateful to all Arivale and TwinsUK participants who consented to using their deidentified data for
1063 research purposes. This work was supported by the M.J. Murdock Charitable Trust (Reference No.
1064 2014096:MNL:11/20/2014, awarded to N.D.P. and L.H.), the National Institutes of Health (NIH)
1065 grants awarded by the National Institute on Aging (NIA) (U19AG023122 and 5U01AG061359), and a
1066 generous gift from K. Carole Ellison (to K.W., T.W., and A.Z.). K.W. was supported by The Uehara
1067 Memorial Foundation (Overseas Postdoctoral Fellowships). C.D. and S.M.G. were supported by the
1068 Washington Research Foundation Distinguished Investigator Award and startup funds from ISB.
1069 TwinsUK is funded by the Wellcome Trust, Medical Research Council, Versus Arthritis, European
1070 Union Horizon 2020, Chronic Disease Research Foundation (CDRF), Zoe Ltd, the National Institute
1071 for Health and Care Research (NIHR) Clinical Research Network (CRN) and Biomedical Research
1072 Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College
1073 London.
1074

1075 **Author Contribution**

1076 K.W., T.W., L.H., N.D.P., and N.R. conceptualized the study. K.W., T.W., A.Z., N.D.P., and N.R.
1077 participated in the study design. K.W., T.W., C.D., B.L., and N.R. performed data analysis and figure
1078 generation. C.D., J.C.E., J.J.H., J.C.L., S.M.G., A.T.M., and L.H. assisted in results interpretation.
1079 J.C.L. and A.T.M. managed the logistics of data collection and integration. K.W., T.W., and N.R.
1080 were the primary authors of the paper, with contributions from all other authors. All authors read and
1081 approved the final manuscript.
1082

1083 **Competing Interests**

1084 J.J.H. has received grants from Pfizer and Novartis for research unrelated to this study. All other
1085 authors declare no competing interests.
1086




Figure 1. Plasma multiomics captured 48–78% of the variance in BMI.

1088
 1089
 1090 **a** Overview of study cohorts and the omics-based Body Mass Index (BMI) model generation. LASSO:
 1091 least absolute shrinkage and selection operator, CV: cross-validation. **b** Correlation between the
 1092 measured and predicted BMIs. The solid line is the ordinary least squares (OLS) linear regression line
 1093 with 95% confidence interval (CI), and the dotted line is measured BMI = predicted BMI. Standard
 1094 measures: OLS linear regression model with sex, age, triglycerides, high-density lipoprotein (HDL)-
 1095 cholesterol, low-density lipoprotein (LDL)-cholesterol, glucose, insulin, and homeostatic model

1096 assessment for insulin resistance (HOMA-IR) as regressors; P : adjusted P -value of two-sided
1097 Pearson's correlation test with the Benjamini–Hochberg method across the five categories. $n = 1,277$
1098 participants. **c, d** Model performance of each fitted BMI model. Out-of-sample R^2 was calculated from
1099 each corresponding hold-out testing set (**c**, Arivale in **d**) or from the external testing set (TwinsUK in
1100 **d**). Metabolomics (full): LASSO model trained by all 766 metabolites of the Arivale dataset,
1101 Metabolomics (restricted): LASSO model trained by the common 489 metabolites in the Arivale and
1102 TwinsUK datasets (see Supplementary Fig. 3). Note that Standard measures and Metabolomics (full)
1103 of Arivale in **d** are the same with corresponding ones in **c**. Data: mean with 95% CI, $n = 10$ models.
1104 ***Adjusted $P < 0.001$ in two-sided Welch's t -test with the Benjamini–Hochberg method across the
1105 four (**c**) or three (**d**) comparisons. **e** Association between omics-inferred BMI and physiological
1106 feature. For each of the 51 numeric physiological features (Supplementary Data 4), β -coefficient was
1107 estimated using OLS linear regression model with the measured or omics-inferred BMI as dependent
1108 variable and sex, age, and ancestry principal components (PCs) as covariates. Presented are the 30
1109 features that were significantly associated with at least one of the BMI types after multiple testing
1110 adjustment with the Benjamini–Hochberg method across the 255 (51 features \times 5 BMI types)
1111 regressions. BMI: measured BMI, MetBMI: metabolomics-inferred BMI, ProtBMI: proteomics-
1112 inferred BMI, ChemBMI: clinical chemistries-inferred BMI, CombiBMI: combined omics-inferred
1113 BMI, PRS: polygenic risk score, n : the number of assessed participants. Data: estimate with 95% CI.
1114 *Adjusted $P < 0.05$, **adjusted $P < 0.01$, ***adjusted $P < 0.001$.
1115




Figure 2. Omics-based BMI estimates captured the variance in BMI better than any single analyte.

a The variables that were retained across all ten combined omics-based Body Mass Index (CombiBMI) models (132 analytes: 77 metabolites, 51 proteins, and 4 clinical laboratory tests). β -coefficient was obtained from the fitted CombiBMI model with least absolute shrinkage and selection operator (LASSO) regression. Each background color corresponds to the analyte category. Data:

1116
1117
1118
1119
1120
1121
1122

1123 median (center line), $[Q_1, Q_3]$ (box limits), $[x_{\min}, x_{\max}]$ (whiskers), where Q_1 and Q_3 are the 1st and 3rd
1124 quartile values, and x_{\min} and x_{\max} are the minimum and maximum values in $[Q_1 - 1.5 \times \text{IQR}, Q_3 + 1.5$
1125 $\times \text{IQR}]$ (IQR: the interquartile range, $Q_3 - Q_1$), respectively; $n = 10$ models. **b–d** Univariate explained
1126 variance in BMI by each metabolite (**b**), protein (**c**), or clinical laboratory test (**d**). BMI was
1127 independently regressed on each of the analytes that were retained in at least one of the ten LASSO
1128 models (209 metabolites, 74 proteins, 41 clinical laboratory tests; Supplementary Data 5), using
1129 ordinary least squares (OLS) linear regression with sex, age, and ancestry principal components (PCs)
1130 as covariates. Multiple testing was adjusted with the Benjamini–Hochberg method across the 210 (**b**),
1131 75 (**c**), or 42 (**d**) regressions, including each omics-based BMI (MetBMI: metabolomics-based BMI,
1132 ProtBMI: proteomics-based BMI, ChemBMI: clinical chemistries-based BMI) model as reference.
1133 Among the analytes that were significantly associated with BMI (180 metabolites, 63 proteins, 30
1134 clinical laboratory tests), only the top 30 significant analytes are presented with their univariate
1135 variances.
1136




Figure 3. Metabolic heterogeneity was responsible for the high rate of misclassification within the standard BMI classes.

1137
1138
1139

1140 **a** Difference of the omics-inferred Body Mass Index (BMI) from the measured BMI (Δ BMI).
1141 MetBMI: metabolomics-inferred BMI, ProtBMI: proteomics-inferred BMI, ChemBMI: clinical
1142 chemistries-inferred BMI, CombiBMI: combined omics-inferred BMI, P : adjusted P -value of two-
1143 sided Pearson's correlation test with the Benjamini–Hochberg method across the six combinations, n :
1144 the number of participants in each BMI class (total $n = 1,277$ participants). The line in histogram panel
1145 indicates the kernel density estimate. **b** Difference in Δ BMI between clinically-defined metabolic
1146 health conditions within the normal or obese BMI class. Significance was assessed using ordinary
1147 least squares (OLS) linear regression with BMI, sex, age, and ancestry principal components (PCs) as
1148 covariates, while adjusting multiple testing with the Benjamini–Hochberg method across the eight
1149 (two BMI classes \times four omics categories) regressions. **c** Misclassification rate of overall cohort or
1150 each BMI class against the omics-inferred BMI class. Range of the previously reported
1151 misclassification rate^{36,37} is highlighted with orange background. Note that the underweight BMI class
1152 is not presented due to small sample size, but its misclassification rate was 80% against CombiBMI
1153 class and 100% against the others. **d**, **e** Difference in the obesity-related clinical blood marker (**d**) or
1154 BMI-associated physiological feature (**e**) between Matched and Mismatched groups within the normal
1155 or obese BMI class. Significance was assessed using OLS linear regression with BMI, sex, age, and
1156 ancestry PCs as covariates, while adjusting multiple testing with the Benjamini–Hochberg method
1157 across the 40 (**d**, 2 BMI classes \times 2 omics categories \times 10 markers) or 216 (**e**, 2 BMI classes \times 4 omics
1158 categories \times 27 features) regressions. Four of the 27 features that were significantly associated with
1159 BMI (Fig. 1c) are representatively presented in **e**, and the other results are found in Supplementary
1160 Data 6. HDL: high-density lipoprotein, LDL: low-density lipoprotein, CRP: C-reactive protein,
1161 HOMA-IR: homeostatic model assessment for insulin resistance, HbA1c: glycated hemoglobin A1c,
1162 25(OH)D: 25-hydroxyvitamin D. **b**, **d**, **e** Data: median (center line), 95% confidence interval (CI)
1163 around median (notch), [Q_1 , Q_3] (box limits), [x_{\min} , x_{\max}] (whiskers), where Q_1 and Q_3 are the 1st and
1164 3rd quartile values, and x_{\min} and x_{\max} are the minimum and maximum values in [$Q_1 - 1.5 \times \text{IQR}$, $Q_3 +$
1165 $1.5 \times \text{IQR}$] (IQR: the interquartile range, $Q_3 - Q_1$), respectively; $n = 373$ (**b**, Healthy in Normal), 49
1166 (**b**, Unhealthy in Normal), 208 (**b**, Healthy in Obese), 241 (**b**, Unhealthy in Obese) participants (see
1167 Supplementary Data 6 for each sample size in **d** and **e**). *Adjusted $P < 0.05$, **adjusted $P < 0.01$,
1168 ***adjusted $P < 0.001$.
1169




Figure 4. Metabolomics-inferred BMI reflected gut microbiome profiles better than BMI.

a Overview of study cohorts and the gut microbiome-based obesity classifier generation. BMI: Body Mass Index, MetBMI: metabolomics-inferred BMI, RF: random forest, CV: cross-validation. **b** Difference in gut microbiome α -diversity between Matched and Mismatched groups within the normal or obese BMI class. Significance was assessed using ordinary least squares (OLS) linear regression with BMI, sex, age, and ancestry principal components (PCs) as covariates, while adjusting multiple testing with the Benjamini–Hochberg method across the 24 (2 BMI classes \times 4 omics categories \times 3 metrics) regressions. ProtBMI: proteomics-inferred BMI, ChemBMI: clinical chemistries-inferred

1170

1171

1172

1173

1174


1175

1176

1177

1178

1179 BMI, CombiBMI: combined omics-inferred BMI, ASV: amplicon sequence variant. Data: median
1180 (center line), 95% confidence interval (CI) around median (notch), $[Q_1, Q_3]$ (box limits), $[x_{\min}, x_{\max}]$
1181 (whiskers), where Q_1 and Q_3 are the 1st and 3rd quartile values, and x_{\min} and x_{\max} are the minimum
1182 and maximum values in $[Q_1 - 1.5 \times \text{IQR}, Q_3 + 1.5 \times \text{IQR}]$ (IQR: the interquartile range, $Q_3 - Q_1$),
1183 respectively. $n = 240$ (Normal), 260 (Obese) participants (see Supplementary Data 6 for each sample
1184 size). *Adjusted $P < 0.05$, **adjusted $P < 0.01$. **c, e** Receiver operator characteristic (ROC) curve of
1185 the gut microbiome-based model classifying participants to the normal vs. obese class in the Arivale
1186 (**c**) or TwinsUK (**e**) cohort. Each ROC curve was generated from the overall participants: $n = 500$ (**c**,
1187 BMI class), 427 (**c**, MetBMI class), 209 (**e**, BMI class), 145 (**e**, MetBMI class) participants. The red
1188 dashed line indicates a random classification line. AUC: area under curve. ** $P < 0.01$ in two-sided
1189 unpaired DeLong's test. **d, f** Comparison of model performance between the BMI and MetBMI
1190 classifiers in the Arivale (**d**) or TwinsUK (**f**) cohort. Out-of-sample metric value was calculated from
1191 each corresponding hold-out testing set. Data: mean with 95% CI, $n = 5$ models. * $P < 0.05$, ** $P <$
1192 0.01 in two-sided Welch's t -test.
1193



1194

1195

1196

Figure 5. Metabolic health of the metabolically obese group was substantially improved following a healthy lifestyle intervention.

1197

1198

1199

1200

1201

1202

1203

a Overview of the longitudinal analysis using omics-inferred Body Mass Index (BMI). BMI: measured BMI, MetBMI: metabolomics-inferred BMI, ProtBMI: proteomics-inferred BMI, ChemBMI: clinical chemistries-inferred BMI, LMM: linear mixed model. **b, c** Longitudinal change in the omics-inferred BMI within the overall cohort (**b**) or within each baseline BMI class (**c**). Average trajectory of each measured or omics-inferred BMI was independently estimated using LMM with random effects for each participant (see Methods) in the overall cohort (**b**) or in each baseline BMI class-stratified group (**c**). **d, e** Longitudinal change in MetBMI of the misclassified participants within

1204 the normal (**d**) or obese (**e**) BMI class. Average trajectory of each BMI or MetBMI was independently
1205 estimated using the above LMM with the baseline misclassification of BMI class against MetBMI
1206 class as additional fixed effects (see Methods) in each baseline BMI class-stratified group. **b–e** The
1207 dashed line corresponds to the baseline value of each estimate. Data: mean with 95% confidence
1208 interval (CI); $n = 608$ (**b**), 222 (**c**, Normal), 185 (**c**, Overweight), 196 (**c**, Obese), 137 (**d**, Matched), 85
1209 (**d**, Mismatched), 139 (**e**, Matched), 57 (**e**, Mismatched) participants.
1210




Figure 6. Plasma analyte correlation network in the metabolically obese group shifted toward a structure observed in metabolically healthier state following a healthy lifestyle intervention.

a Cross-omic interactions modified by metabolomics-inferred Body Mass Index (MetBMI) and days in the program. For each of the 608,856 pairwise relationships of plasma analytes (766 metabolites,

1211
1212
1213
1214
1215

1216 274 proteomics, 64 clinical laboratory tests), the baseline relationship between analyte–analyte pair
1217 and MetBMI within the Arivale sub-cohort (Fig. 5a; 608 participants) was assessed using their
1218 interaction term in each generalized linear model (GLM; see Methods), while adjusting multiple
1219 testing with the Benjamini–Hochberg method. The 100 analyte–analyte pairs (82 metabolites, 33
1220 proteins, 16 clinical laboratory tests; Supplementary Data 7) that were significantly modified by the
1221 baseline MetBMI are presented. For each of these 100 pairs, the longitudinal relationship between
1222 analyte–analyte pair and days in the program within the metabolically obese group (i.e., the baseline
1223 obese MetBMI class; 182 participants) was further assessed using their interaction term in each
1224 generalized estimating equation (GEE; see Methods), while adjusting multiple testing with the
1225 Benjamini–Hochberg method. The 27 analyte–analyte pairs (21 metabolites, 3 proteins, 3 clinical
1226 laboratory tests) that were significantly modified by days in the program are highlighted by line width
1227 and label font size. **b, c** Representative examples of the analyte–analyte pair that was significantly
1228 modified by both baseline MetBMI (**b**) and days in the program (**c**) in **a**. The solid line in each panel is
1229 the ordinary least squares (OLS) linear regression line with 95% confidence interval (CI). $n = 530$ (**b**,
1230 left), 553 (**b**, center), 566 (**b**, right) participants; $n = 324$ (**c**, left), 339 (**c**, center), 347 (**c**, right)
1231 measurements from the 182 participants of the metabolically obese group. Of note, data points outside
1232 of plot range are trimmed in these presentations.
1233